{"content":"<li class=\"n-box-item date-title\" data-end=\"1505361599\" data-start=\"1505275200\" data-txt=\"Monday, December 23, 2019\">Wednesday, September 13, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3295324\" data-ts=\"1505346273\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIA\" target=\"_blank\">VIA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295324-viacom-sees-boost-from-streaming-plans-mtv-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viacom sees boost from streaming plans, MTV ratings</a></h4><ul>   <li>Viacom shares (<a href='https://seekingalpha.com/symbol/VIA' title='Viacom Inc.'>VIA</a> <font color='green'>+4.9%</font>, <a href='https://seekingalpha.com/symbol/VIAB' title='Viacom Inc.'>VIAB</a> <font color='green'>+3%</font>) made a healthy gain a day after news that the company would be putting its networks into a <a href=\"https://seekingalpha.com/news/3294760-media-companies-band-together-sports-free-streaming\" target=\"_blank\">sports-free streaming package</a> to launch this year -- and with news that its MTV has shown its <a href=\"https://www.reuters.com/article/us-viacom-mtv/viacoms-mtv-sees-first-summer-ratings-growth-in-six-years-idUSKCN1BO189\" target=\"_blank\">first summer ratings growth in six years</a>.</li>    <li>That suggests the turnaround under its new CEO Bob Bakish is under way, the company says.</li>    <li>Several Viacom networks (the company also owns Nickelodeon, Comedy Central and BET) saw flagging ratings for some time before <a href=\"https://seekingalpha.com/news/3218788-viacom-taps-international-chief-bakish-acting-ceo-president\" target=\"_blank\">Bakish's hiring last fall</a> in the wake of disputes with former CEO Philippe Dauman.</li>    <li>But getting MTV turned was key as it makes up about 15% of Viacom's media network revenue, Jefferies' John Janedis points out.</li><li>MTV has a ways to go to reverse years of audience erosion, however.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295324\" data-linked=\"Viacom sees boost from streaming plans, MTV ratings\" data-tweet=\"$VIA $VIA $VIAB - Viacom sees boost from streaming plans, MTV ratings https://seekingalpha.com/news/3295324-viacom-sees-boost-from-streaming-plans-mtv-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3295324-viacom-sees-boost-from-streaming-plans-mtv-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295310\" data-ts=\"1505338512\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295310-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='green'>+11.5%</font>. <a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a> <font color='green'>+5.3%</font>. <a href='https://seekingalpha.com/symbol/LAKE' title='Lakeland Industries, Inc.'>LAKE</a> <font color='green'>+4.3%</font>. <a href='https://seekingalpha.com/symbol/ACTG' title='Acacia Research Corporation'>ACTG</a> <font color='green'>+3.9%</font>. <a href='https://seekingalpha.com/symbol/SALT' title='Scorpio Bulkers Inc'>SALT</a> <font color='green'>+3.6%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a> <font color='red'>-8.3%</font>. <a href='https://seekingalpha.com/symbol/VNDA' title='Vanda Pharmaceuticals Inc.'>VNDA</a> <font color='red'>-5.3%</font>. <a href='https://seekingalpha.com/symbol/MXWL' title='Maxwell Technologies, Inc.'>MXWL</a> <font color='red'>-3.7%</font>. <a href='https://seekingalpha.com/symbol/KONA' title='Kona Grill, Inc.'>KONA</a> <font color='red'>-3.6%</font>. <a href='https://seekingalpha.com/symbol/USFD' title='US Foods Holding'>USFD</a> <font color='red'>-2.7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295310\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$THC $UNFI $LAKE - After Hours Gainers / Losers https://seekingalpha.com/news/3295310-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3295310-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295299\" data-ts=\"1505336379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SMMT\" target=\"_blank\">SMMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295299-summit-therapeutics-readies-15m-equity-offering-shares-down-11-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Summit Therapeutics readies $15M equity offering; shares down 11% after hours</a></h4><ul><li>Summit Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SMMT' title='Summit Therapeutics'>SMMT</a>) slumps&nbsp;<font color='red'>11%</font>&nbsp;after hours on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16940200-summit-therapeutics-announces-proposed-public-offering-15_0-million-american-depositary\" target=\"_blank\">announcement </a>of a $15M public offering of American Depositary Shares (ADSs) pursuant to a shelf registration. Price, volume and terms have yet to be released.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295299\" data-linked=\"Summit Therapeutics readies $15M equity offering; shares down 11% after hours\" data-tweet=\"$SMMT - Summit Therapeutics readies $15M equity offering; shares down 11% after hours https://seekingalpha.com/news/3295299-summit-therapeutics-readies-15m-equity-offering-shares-down-11-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3295299-summit-therapeutics-readies-15m-equity-offering-shares-down-11-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295297\" data-ts=\"1505336169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LAKE\" target=\"_blank\">LAKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295297-lakeland-fiscal-q2-top-line-up-7-earnings-up-29-shares-ahead-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lakeland fiscal Q2 top line up 7%; earnings up 29%; shares ahead 4% after hours</a></h4><ul><li>Lakeland Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/LAKE' title='Lakeland Industries, Inc.'>LAKE</a>) <a href=\"https://seekingalpha.com/pr/16940116-lakeland-industries-inc-reports-29-percent-increase-net-income-fiscal-2018-second-quarter\" target=\"_blank\">fiscal Q2 results</a> ($M): Net Sales: 23.9 (+7.2%); Net Income: 1.8 (+28.7%); EPS: 0.25 (+25.0%).</li><li>Sales in U.S., Asia and ROW offset softness in Europe.</li><li>Cash balance: $13.2M (+27%).</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295297\" data-linked=\"Lakeland fiscal Q2 top line up 7%; earnings up 29%; shares ahead 4% after hours\" data-tweet=\"$LAKE - Lakeland fiscal Q2 top line up 7%; earnings up 29%; shares ahead 4% after hours https://seekingalpha.com/news/3295297-lakeland-fiscal-q2-top-line-up-7-earnings-up-29-shares-ahead-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3295297-lakeland-fiscal-q2-top-line-up-7-earnings-up-29-shares-ahead-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295294\" data-ts=\"1505335781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRIS\" target=\"_blank\">CRIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295294-curis-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Curis readies stock offering</a></h4><ul><li>Curis (NASDAQ:<a href='https://seekingalpha.com/symbol/CRIS' title='Curis, Inc.'>CRIS</a>) <a href=\"https://seekingalpha.com/pr/16940117-curis-announces-proposed-public-offering-common-stock\" target=\"_blank\">commences </a>a public offering of 20M shares of common stock. Price and terms have yet to be announced. Net proceeds will help fund the development of CUDC-907, CA-170, CA-327 and CA-4948, potential acquisitions, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295294\" data-linked=\"Curis readies stock offering\" data-tweet=\"$CRIS - Curis readies stock offering https://seekingalpha.com/news/3295294-curis-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3295294-curis-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295291\" data-ts=\"1505335382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/THC\" target=\"_blank\">THC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295291-wsj-reports-tenet-mulling-sale-shares-up-15-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ reports Tenet mulling sale; shares up 15% after hours</a></h4><ul><li>The Wall Street Journal <a href=\"https://www.wsj.com/articles/tenet-healthcare-is-exploring-options-including-a-possible-sale-of-the-company-1505334783\" target=\"_blank\">reports </a>that Tenet Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a>) is exploring strategic alternatives, including a possible sale of the company.</li><li>The stock has tried to rally twice this year but retraced both times. The company missed consensus revenue expectations the past two quarters and EPS views three of the past four.</li><li>Shares are up&nbsp;<font color='green'>15%</font>&nbsp;after hours on robust volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295291\" data-linked=\"WSJ reports Tenet mulling sale; shares up 15% after hours\" data-tweet=\"$THC - WSJ reports Tenet mulling sale; shares up 15% after hours https://seekingalpha.com/news/3295291-wsj-reports-tenet-mulling-sale-shares-up-15-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3295291-wsj-reports-tenet-mulling-sale-shares-up-15-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295288\" data-ts=\"1505335069\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPZM\" target=\"_blank\">EPZM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295288-epizyme-readies-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Epizyme readies stock offering</a></h4><ul><li>Epizyme (NASDAQ:<a href='https://seekingalpha.com/symbol/EPZM' title='Epizyme'>EPZM</a>) is <a href=\"https://seekingalpha.com/pr/16940104-epizyme-announces-proposed-public-offering-common-stock\" target=\"_blank\">preparing </a>a $120M public offering of common stock. Price, volume and terms have yet to be announced. Net proceeds will help fund global development cost of tazemetostat outside of Japan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295288\" data-linked=\"Epizyme readies stock offering\" data-tweet=\"$EPZM - Epizyme readies stock offering https://seekingalpha.com/news/3295288-epizyme-readies-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3295288-epizyme-readies-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295286\" data-ts=\"1505334911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARRY\" target=\"_blank\">ARRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295286-array-readies-equity-offering-shares-down-8-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Array readies equity offering; shares down 8% after hours</a></h4><ul><li>Array BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ARRY' title='Array BioPharma Inc.'>ARRY</a>) slips&nbsp;<font color='red'>8%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16940111-array-biopharma-announces-proposed-public-offering-common-stock\" target=\"_blank\">announcement </a>of a $175M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295286\" data-linked=\"Array readies equity offering; shares down 8% after hours\" data-tweet=\"$ARRY - Array readies equity offering; shares down 8% after hours https://seekingalpha.com/news/3295286-array-readies-equity-offering-shares-down-8-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3295286-array-readies-equity-offering-shares-down-8-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295284\" data-ts=\"1505334741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNDA\" target=\"_blank\">VNDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295284-vandas-tradipitant-shows-mixed-results-in-mid-stage-dermatitis-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vanda&#39;s tradipitant shows mixed results in mid-stage dermatitis study</a></h4><ul><li>A Phase 2 clinical trial evaluating Vanda Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VNDA' title='Vanda Pharmaceuticals Inc.'>VNDA</a>) tradipitant in patients with atopic dermatitis with chronic pruritus (itching) showed a clinically meaningful and statistically significant <a href=\"https://seekingalpha.com/pr/16940139-vandas-tradipitant-improves-itch-disease-severity-patients-atopic-dermatitis\" target=\"_blank\">treatment effect</a> on a number of measures but fell short on others.</li><li>The 168-subject study randomized participants 1:1 to receive either 85 mg of tradipitant twice daily or placebo for eight weeks. On itch outcomes in the intent-to-treat population, the results favored tradipitant but two of four measures were not statistically valid. Quality of life measures were also split, one statistically valid and the other not.</li><li>The proportion of patients who achieved at least a 40-point improvement from baseline (the most profound improvement in symptoms) favored tradipitant and was statistically significant (52.6% vs. 34.7%; p=0.037).</li><li>Vanda licensed tradipitant, an NK-1R antagonist, from Eli Lilly in April 2012. It plans to meet with the FDA to clarify the next steps in development.</li><li>Management will host a conference call tomorrow, September 14, at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295284\" data-linked=\"Vanda&#39;s tradipitant shows mixed results in mid-stage dermatitis study\" data-tweet=\"$VNDA - Vanda&#39;s tradipitant shows mixed results in mid-stage dermatitis study https://seekingalpha.com/news/3295284-vandas-tradipitant-shows-mixed-results-in-mid-stage-dermatitis-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3295284-vandas-tradipitant-shows-mixed-results-in-mid-stage-dermatitis-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295281\" data-ts=\"1505334632\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MGI\" target=\"_blank\">MGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295281-chinese-deal-targets-slip-after-trump-rejects-lattice-takeover\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Other Chinese deal targets slip after Trump rejects Lattice takeover</a></h4><ul><li>In a rare move, the president - citing national security reasons - <a href=\"https://seekingalpha.com/news/3295265-bloomberg-trump-blocks-chinese-semiconductor-acquisition\" target=\"_blank\">has blocked a</a> Chinese private-equity firm's buyout of Lattice Semiconductor.</li><li>Moneygram's (NYSE:<a href='https://seekingalpha.com/symbol/MGI' title='MoneyGram International, Inc.'>MGI</a>) takeover by Ant Financial is currently under U.S. review. Its shares are&nbsp;<font color='red'>down 2.4%</font>&nbsp;after hours.</li><li>Genworth's (NYSE:<a href='https://seekingalpha.com/symbol/GNW' title='Genworth Financial, Inc.'>GNW</a>) sale to China Oceanwide is also pending. It's&nbsp;<font color='red'>down 0.25%&nbsp;</font>after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295281\" data-linked=\"Other Chinese deal targets slip after Trump rejects Lattice takeover\" data-tweet=\"$MGI $MGI $GNW - Other Chinese deal targets slip after Trump rejects Lattice takeover https://seekingalpha.com/news/3295281-chinese-deal-targets-slip-after-trump-rejects-lattice-takeover?source=tweet\" data-url=\"https://seekingalpha.com/news/3295281-chinese-deal-targets-slip-after-trump-rejects-lattice-takeover\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295273\" data-ts=\"1505334201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ON\" target=\"_blank\">ON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295273-goldman-sachs-downgrades-on-semiconductor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs downgrades ON Semiconductor</a></h4><ul><li>        ON Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a>) closes&nbsp;<font color='red'>down 1%&nbsp;</font>today after a Goldman Sachs downgrade from Buy to Neutral with an $18 price target.</li><li>               Analyst Mark Delaney says company&rsquo;s 2018 EPS sits slightly below consensus and the stock trades within 5% of the firm&rsquo;s price target.&nbsp;</li><li>               Source: <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+ON+Semiconductor+%28ON%29+to+Neutral/13289964.html\" target=\"_blank\">StreetInsider</a>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3286343-needham-upgrades-semi-strong-buy-shares-6_5-percent\" target=\"_blank\">Needham upgrades ON Semi to Strong Buy; shares up 6.5%</a> (Aug. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295273\" data-linked=\"Goldman Sachs downgrades ON Semiconductor\" data-tweet=\"$ON - Goldman Sachs downgrades ON Semiconductor https://seekingalpha.com/news/3295273-goldman-sachs-downgrades-on-semiconductor?source=tweet\" data-url=\"https://seekingalpha.com/news/3295273-goldman-sachs-downgrades-on-semiconductor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295271\" data-ts=\"1505333878\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295271-lifelock-signups-up-10x-after-equifax-hack\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LifeLock signups up 10x after Equifax hack</a></h4><ul><li>&ldquo;It was crazy,&rdquo; says Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) VP Fran Rosch, of the days following disclosure of the Equifax cyber-attack. \"It has been like an earthquake.\"</li><li>Since the breach, Symantec's LifeLock <a href=\"https://www.bloomberg.com/news/articles/2017-09-13/after-the-equifax-hack-lifelock-sign-ups-jump-tenfold\" target=\"_blank\">has seen six times its</a> normal web traffic, and signups per hour are up 10x. Rosch: \"We&rsquo;re over 100K new members and counting since the breach ... Most are paying the full price, rather than discounts.\"</li><li>Though&nbsp;<font color='red'>down 1.9%</font>&nbsp;today, Symantec is&nbsp;<font color='green'>higher by more than 10%&nbsp;</font>since the Equifax news hit on Thursday night.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295271\" data-linked=\"LifeLock signups up 10x after Equifax hack\" data-tweet=\"$SYMC $NLOK - LifeLock signups up 10x after Equifax hack https://seekingalpha.com/news/3295271-lifelock-signups-up-10x-after-equifax-hack?source=tweet\" data-url=\"https://seekingalpha.com/news/3295271-lifelock-signups-up-10x-after-equifax-hack\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295265\" data-ts=\"1505333697\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LSCC\" target=\"_blank\">LSCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295265-trump-blocks-chinese-semiconductor-acquisition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump blocks Chinese semiconductor acquisition</a></h4><ul><li>President Trump has <a href=\"https://www.bloomberg.com/news/articles/2017-09-13/trump-blocks-china-backed-bid-for-chipmaker-over-security-risk\" target=\"_blank\">blocked </a>Chinese private equity firm Canyon Bridge Capital Partners from buying Lattice Semiconductor (NASDAQ:<a href='https://seekingalpha.com/symbol/LSCC' title='Lattice Semiconductor Corporation'>LSCC</a>).</li><li>Trump followed the recommendation of the Committee on Foreign investment in the U.S., which was reportedly against the deal on national security concerns about Lattice&rsquo;s tech aiding the Chinese military.</li><li>The acquisition was proposed at $1.3B.</li><li>Lattice Semiconductor shares are&nbsp;<font color='red'>down 0.35%</font>&nbsp;aftermarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3293245-lattice-semiconductor-seeking-trumps-direct-approval-acquisition\" target=\"_blank\">Lattice Semiconductor seeking Trump's direct approval for acquisition</a> (Sept. 1)</li><li>Update: Statement from Treasury Secretary Steven Mnuchin: \"\"Consistent with the administration&rsquo;s commitment to take all actions necessary to ensure the protection of U.S. national security, the president issued an order prohibiting the acquisition.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3295265\" data-linked=\"Trump blocks Chinese semiconductor acquisition\" data-tweet=\"$LSCC - Trump blocks Chinese semiconductor acquisition https://seekingalpha.com/news/3295265-trump-blocks-chinese-semiconductor-acquisition?source=tweet\" data-url=\"https://seekingalpha.com/news/3295265-trump-blocks-chinese-semiconductor-acquisition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295254\" data-ts=\"1505332973\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KLAC\" target=\"_blank\">KLAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295254-kla-tencor-down-after-goldman-sachs-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KLA-Tencor down after Goldman Sachs downgrade</a></h4><ul><li>        KLA-Tencor (NASDAQ:<a href='https://seekingalpha.com/symbol/KLAC' title='KLA-Tencor Corporation'>KLAC</a>) shares close&nbsp;<font color='red'>down 1.24%</font>&nbsp;today after a Goldman Sachs downgrade from Buy to Neutral and a price target cut from $108 to $97.</li><li>                  Analyst Toshiya Hari cites pessimism tied to foundry expectation reduction for the year.    </li><li>               EPS estimates: FY18, $7.20 (up from $7.08); FY19, $6.90 (down from $8.16); FY20, $7.54 (down from $8.21).&nbsp;</li><li>               Source: <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Downgrades+KLA-Tencor+%28KLAC%29+to+Neutral/13290628.html\" target=\"_blank\">StreetInsider</a>. &nbsp;&nbsp; &nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3295254\" data-linked=\"KLA-Tencor down after Goldman Sachs downgrade\" data-tweet=\"$KLAC - KLA-Tencor down after Goldman Sachs downgrade https://seekingalpha.com/news/3295254-kla-tencor-down-after-goldman-sachs-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3295254-kla-tencor-down-after-goldman-sachs-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295245\" data-ts=\"1505332062\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMPV\" target=\"_blank\">IMPV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295245-imperva-down-after-elliott-associates-stake-drop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Imperva down after Elliott Associates stake drop</a></h4><ul><li>        Imperva (NASDAQ:<a href='https://seekingalpha.com/symbol/IMPV' title='Imperva, Inc.'>IMPV</a>) shares&nbsp;<font color='red'>down 4.95%&nbsp;</font>after a regulatory filing revealed that Elliott Associates reduced its active stake to 9.5%. &nbsp;</li><li>        <a href=\"https://www.sec.gov/Archives/edgar/data/904495/000101359417000671/imperva13da2-090817.htm\" target=\"_blank\">Filing</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3282484-imperva-beats-0_19-revenue-line\" target=\"_blank\">Imperva beats by $0.19,  revenue in-line</a> (July 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295245\" data-linked=\"Imperva down after Elliott Associates stake drop\" data-tweet=\"$IMPV - Imperva down after Elliott Associates stake drop https://seekingalpha.com/news/3295245-imperva-down-after-elliott-associates-stake-drop?source=tweet\" data-url=\"https://seekingalpha.com/news/3295245-imperva-down-after-elliott-associates-stake-drop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295235\" data-ts=\"1505330264\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLSE\" target=\"_blank\">PLSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295235-selloff-in-pulse-bio-continues-shares-down-23\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Selloff in Pulse Bio continues, shares down 23%</a></h4><ul><li>Thinly traded micro cap Pulse Biosciences (<a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-23%</font>) continues its slide on more than a 4x surge in volume. Shares have lost almost half their value this week after the company pulled its U.S. marketing application for PulseTx.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294583-trading-pulse-biosciences-halted-pending-news\" target=\"_blank\">Trading in Pulse Biosciences halted pending news</a> (Sept. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295235\" data-linked=\"Selloff in Pulse Bio continues, shares down 23%\" data-tweet=\"$PLSE - Selloff in Pulse Bio continues, shares down 23% https://seekingalpha.com/news/3295235-selloff-in-pulse-bio-continues-shares-down-23?source=tweet\" data-url=\"https://seekingalpha.com/news/3295235-selloff-in-pulse-bio-continues-shares-down-23\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295232\" data-ts=\"1505329106\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DHI\" target=\"_blank\">DHI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295232-d-r-horton-seen-missing-guidance-after-hurricanes-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">D.R. Horton seen missing guidance after hurricanes; shares down 2%</a></h4><ul><li>Speaking at the RBC conference, CEO Bill Wheat says the company's Q4 closings will fall short of guidance (which had been 88%-90% of backlog conversion).</li><li>Will this push business into 2018? Too early to assess, he says, thanks to possible labor delays and competition with rebuilding efforts.</li><li>Source: Jeremy Crooke at Bloomberg</li><li><a href='https://seekingalpha.com/symbol/DHI' title='D. R. Horton Inc.'>DHI</a>&nbsp;<font color='red'>-2.15%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3295232\" data-linked=\"D.R. Horton seen missing guidance after hurricanes; shares down 2%\" data-tweet=\"$DHI - D.R. Horton seen missing guidance after hurricanes; shares down 2% https://seekingalpha.com/news/3295232-d-r-horton-seen-missing-guidance-after-hurricanes-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3295232-d-r-horton-seen-missing-guidance-after-hurricanes-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295231\" data-ts=\"1505329034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDL\" target=\"_blank\">LDL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295231-lydallplus-10-after-sidoti-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lydall +10% after Sidoti upgrade</a></h4><ul><li>Lydall (<a href='https://seekingalpha.com/symbol/LDL' title='Lydall, Inc.'>LDL</a> <font color='green'>+10.5%</font>) rallies after Sidoti upgrades the stock to Buy from Neutral.</li><li>The firm notes that Lydall generates a significant portion of its business from the light truck segment, which has held up in comparison to the overall automobile industry.</li><li>Lydall has been sold off by investors over the last 90 days amid concerns over broad auto weakness.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295231\" data-linked=\"Lydall +10% after Sidoti upgrade\" data-tweet=\"$LDL - Lydall +10% after Sidoti upgrade https://seekingalpha.com/news/3295231-lydallplus-10-after-sidoti-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3295231-lydallplus-10-after-sidoti-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295229\" data-ts=\"1505328931\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295229-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/DLB' title='Dolby Laboratories, Inc.'>DLB</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/TRHC' title='Tabula Rasa HealthCare'>TRHC</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ANY' title='Sphere 3D Corp.'>ANY</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/KEM' title='KEMET Corp.'>KEM</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/IMPV' title='Imperva, Inc.'>IMPV</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295229\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$EGAN $DLB $GDS - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3295229-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3295229-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295227\" data-ts=\"1505328684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLR\" target=\"_blank\">DLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295227-data-center-reits-slump-vc-speech-predicts-fade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Data center REITs slump as VC speech predicts their fade</a></h4><ul>   <li>Data center REITs are moving today after Social Capital's Chamath Palihapitiya used a Delivering Alpha presentation to predict their (eventual) obsolescence.</li>    <li>Shrinking chips is the reason, he says, which obviously cuts the need for real estate.</li>    <li>Word that Google may have developed its own chip that can run 50% of its computing on 10% of the silicon has him reading that \"We can literally take a rack of servers that can basically replace seven or eight data centers and park it, drive it in an RV and park it beside a data center. Plug it into some air conditioning and power and it will take those data centers out of business.\"</li>    <li>On the move: Digital Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/DLR' title='Digital Realty Trust, Inc.'>DLR</a>) is <font color='red'>off 3.6%</font>, while DuPont Fabros (NYSE:<a href='https://seekingalpha.com/symbol/DFT' title='DuPont Fabros Technology'>DFT</a>) is <font color='red'>3.4% lower</font>. CoreSite Realty (NYSE:<a href='https://seekingalpha.com/symbol/COR' title='CoreSite Realty Corporation'>COR</a>) is <font color='red'>down 3.5%</font>, and QTS Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/QTS' title='QTS Realty Trust, Inc.'>QTS</a>) <font color='red'>down 3%</font>.</li>    <li>CyrusOne (NASDAQ:<a href='https://seekingalpha.com/symbol/CONE' title='CyrusOne'>CONE</a>) is <font color='red'>2.4% lower</font> and Equinix (NASDAQ:<a href='https://seekingalpha.com/symbol/EQIX' title='Equinix, Inc.'>EQIX</a>) is <font color='red'>down 2.1%</font>.</li>    <li>Starwood's Barry Sternlicht says he's been avoiding the space since talking with Palihapitiya about his ideas. \"It's not going to happen overnight, but investing isn't about overnight, and if you can see the train wrecks coming you can take advantage of them.\"</li>    <li>Source: Bloomberg</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295227\" data-linked=\"Data center REITs slump as VC speech predicts their fade\" data-tweet=\"$DLR $DLR $DFT - Data center REITs slump as VC speech predicts their fade https://seekingalpha.com/news/3295227-data-center-reits-slump-vc-speech-predicts-fade?source=tweet\" data-url=\"https://seekingalpha.com/news/3295227-data-center-reits-slump-vc-speech-predicts-fade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>125&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295221\" data-ts=\"1505327168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WLL\" target=\"_blank\">WLL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295221-whiting-petroleum-downgraded-morgan-stanley-jumps-5-anyway\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whiting Petroleum downgraded at Morgan Stanley but jumps 5% anyway</a></h4><ul>     <li>Whiting Petroleum (<a href='https://seekingalpha.com/symbol/WLL' title='Whiting Petroleum Corporation'>WLL</a> <font color='green'>+5.4%</font>) zips higher in spite of a Morgan&nbsp;Stanley <a href=\"http://www.barrons.com/articles/morgan-stanley-picked-a-bad-day-to-downgrade-whiting-1505318717\" target=\"_blank\">downgrade</a> to Underweight from Equal Weight, citing a weak risk-reward relative to peers, but oil and gas stocks are rallying on the back of today's <a href=\"https://seekingalpha.com/news/3295203-crude-oil-shoots-higher-signs-tightening-supply\" target=\"_blank\">jump in crude oil prices</a>.</li>     <li>The downgrade is part of a larger report that predicts crude oil prices staying in a $45-$60/bbl band amid continued technology gains, providing a more positive risk-reward for Permian-focused operators; Stanley believes the E&amp;Ps best positioned for this environment are EOG&nbsp;Resources (<a href='https://seekingalpha.com/symbol/EOG' title='EOG Resources, Inc.'>EOG</a> <font color='green'>+2.2%</font>), Pioneer Natural Resources (<a href='https://seekingalpha.com/symbol/PXD' title='Pioneer Natural Resources Company'>PXD</a> <font color='green'>+4.4%</font>), Parsley Energy (<a href='https://seekingalpha.com/symbol/PE' title='Parsley Energy, Inc.'>PE</a> <font color='green'>+4.4%</font>), Diamondback Energy (<a href='https://seekingalpha.com/symbol/FANG' title='Diamondback Energy'>FANG</a> <font color='green'>+3.3%</font>)&nbsp;and Devon Energy (<a href='https://seekingalpha.com/symbol/DVN' title='Devon Energy Corporation'>DVN</a> <font color='green'>+3.5%</font>).</li>     <li>The firm says EOG has climbed to the top of its U.S. E&amp;P coverage universe, more than justifying its premium vs. the rest of the group, and driving an upgrade to Overweight from Equal Weight.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295221\" data-linked=\"Whiting Petroleum downgraded at Morgan Stanley but jumps 5% anyway\" data-tweet=\"$WLL $WLL $EOG - Whiting Petroleum downgraded at Morgan Stanley but jumps 5% anyway https://seekingalpha.com/news/3295221-whiting-petroleum-downgraded-morgan-stanley-jumps-5-anyway?source=tweet\" data-url=\"https://seekingalpha.com/news/3295221-whiting-petroleum-downgraded-morgan-stanley-jumps-5-anyway\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295215\" data-ts=\"1505325968\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295215-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/NGL' title='NGL Energy Partners LP'>NGL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/HBM' title='Hudbay Minerals Inc Ordinary Sh'>HBM</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295215\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$EGO $AMRS $NGL - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3295215-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3295215-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295211\" data-ts=\"1505324948\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRBT\" target=\"_blank\">IRBT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295211-shares-of-irobot-plunge-on-analyst-comments-rising-competition\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shares of iRobot plunge on analyst comments about rising competition</a></h4><ul><li>           Shares of iRobot (NASDAQ:<a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a>)&nbsp;<font color='red'>plunge 12.77%</font>&nbsp;today after Spruce Point Capital questioned the company&rsquo;s ability to fend off SharkNinja&rsquo;s latest product, per <a href=\"https://www.ft.com/content/9dda1b12-52dc-3acc-aa1a-b316d014f4ae\" target=\"_blank\">Financial Times</a>. &nbsp; </li><li>        The firm&rsquo;s report reiterates a &ldquo;strong sell&rdquo; rating and believes SharkNinja could take the top spot in the robotic vacuum market by offering similar products with similar marketing at price points about $250 lower than iRobot.</li><li>                  Spruce Point says iRobot currently has about 88% of the US market but that it&rsquo;s &ldquo;inevitable&rdquo; the company will lose market and margins to SharkNinja rising competition.    &nbsp;  </li></ul><div class=\"tiny-share-widget\" data-id=\"3295211\" data-linked=\"Shares of iRobot plunge on analyst comments about rising competition\" data-tweet=\"$IRBT - Shares of iRobot plunge on analyst comments about rising competition https://seekingalpha.com/news/3295211-shares-of-irobot-plunge-on-analyst-comments-rising-competition?source=tweet\" data-url=\"https://seekingalpha.com/news/3295211-shares-of-irobot-plunge-on-analyst-comments-rising-competition\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295210\" data-ts=\"1505324898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295210-deutsche-bank-likes-alexion-sees-8-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deutsche Bank likes Alexion, sees 8% upside</a></h4><ul><li>Deutsche Bank has raised its price target on Alexion Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='green'>+1.2%</font>) to $158 (8% upside) from $153 citing the expected benefits of its previously announced restructuring.</li><li>Source: Bloomberg</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294839-alexion-confirms-move-boston-20-percent-cut-workforce-shares-2-percent-premarket\" target=\"_blank\">Alexion confirms move to Boston, 20% cut in workforce; shares up 2% premarket</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295210\" data-linked=\"Deutsche Bank likes Alexion, sees 8% upside\" data-tweet=\"$ALXN - Deutsche Bank likes Alexion, sees 8% upside https://seekingalpha.com/news/3295210-deutsche-bank-likes-alexion-sees-8-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3295210-deutsche-bank-likes-alexion-sees-8-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295209\" data-ts=\"1505324114\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGI\" target=\"_blank\">TGI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295209-boeing-suppliers-mull-increased-787-production\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing suppliers mull increased 787 production</a></h4><ul><li>Addressing a conference a short time ago, Boeing CEO Dennis Muilenburg said the <a href=\"https://seekingalpha.com/news/3295206-boeing-move-ceo-presents\" target=\"_blank\">company will boost</a> Dreamliner production to 14 per month in 2019 (from the current 12).</li><li>Down prior to the talk, Boeing is now&nbsp;<font color='green'>higher by 1%</font>.</li><li>Suppliers like Triumph Group (<a href='https://seekingalpha.com/symbol/TGI' title='Triumph Group, Inc.'>TGI</a> <font color='red'>-0.2%</font>), Spirit Aero (<a href='https://seekingalpha.com/symbol/SPR' title='Spirit AeroSystems Holdings, Inc.'>SPR</a> <font color='green'>+0.6%</font>), Rockwell Collins (<a href='https://seekingalpha.com/symbol/COL' title='Rockwell Collins, Inc.'>COL</a> <font color='green'>+0.1%</font>), and UTX (<a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='green'>+0.1%</font>) are active, but not necessarily headed too much higher.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295209\" data-linked=\"Boeing suppliers mull increased 787 production\" data-tweet=\"$TGI $TGI $SPR - Boeing suppliers mull increased 787 production https://seekingalpha.com/news/3295209-boeing-suppliers-mull-increased-787-production?source=tweet\" data-url=\"https://seekingalpha.com/news/3295209-boeing-suppliers-mull-increased-787-production\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295207\" data-ts=\"1505323246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFL\" target=\"_blank\">SFL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295207-ship-financeplus-5-after-signing-restructuring-deal-seadrill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ship Finance +5% after signing restructuring deal with Seadrill</a></h4><ul>     <li>Ship Finance International (<a href='https://seekingalpha.com/symbol/SFL' title='Ship Finance International Limited'>SFL</a> <font color='green'>+4.7%</font>) is higher on news of its <a href=\"https://seekingalpha.com/pr/16938958-sfl-signing-restructuring-agreement-seadrill-limited\" target=\"_blank\">restructuring agreement</a> in connection with <a href=\"https://seekingalpha.com/news/3295011-seadrill-files-bankruptcy-updated\" target=\"_blank\">Seadrill's Chapter 11 restructuring</a>.</li>     <li>As      part of SDRL's plan, SFL and three subsidiaries which own and lease the <em>West Linus</em>, <em>West Hercules</em> and <em>West Taurus</em> drilling rigs to Seadrill agree to reduce the contractual charter hire by ~30% for five years beginning next year, with the reduced amounts added back in the period thereafter.</li>     <li>The banks who finance the three rigs agree to extend the loan period by roughyl four years, with reduced amortization in the extension period compared to today's level.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295207\" data-linked=\"Ship Finance +5% after signing restructuring deal with Seadrill\" data-tweet=\"$SFL - Ship Finance +5% after signing restructuring deal with Seadrill https://seekingalpha.com/news/3295207-ship-financeplus-5-after-signing-restructuring-deal-seadrill?source=tweet\" data-url=\"https://seekingalpha.com/news/3295207-ship-financeplus-5-after-signing-restructuring-deal-seadrill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295206\" data-ts=\"1505322670\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BA\" target=\"_blank\">BA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295206-boeing-on-move-ceo-presents\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boeing on the move as CEO presents</a></h4><ul><li>Speaking at the Morgan Stanley Laguna Conference, Boeing (NYSE:<a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a>) CEO Dennis Muilenburg says the company expects to raise 787 production to 14 per month in 2019.</li><li>The share price has moved from modestly lower to modestly higher since Muilenburg began speakin.</li><li><a href=\"http://investors.boeing.com/investors/events-and-presentations/default.aspx\" target=\"_blank\">Webcast and slides here</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3295206\" data-linked=\"Boeing on the move as CEO presents\" data-tweet=\"$BA - Boeing on the move as CEO presents https://seekingalpha.com/news/3295206-boeing-on-move-ceo-presents?source=tweet\" data-url=\"https://seekingalpha.com/news/3295206-boeing-on-move-ceo-presents\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295204\" data-ts=\"1505322585\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCLR\" target=\"_blank\">OCLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295204-oclaro-up-4_4-amid-halftime-cnbc-talk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oclaro up 4.4% amid halftime CNBC talk</a></h4><ul>   <li>Opticals firm Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>) has <font color='green'>jumped 4.4%</font> as <a href=\"https://www.instagram.com/p/BY_RDffAbjo/\" target=\"_blank\">Jon Najarian</a> and company discuss unusual options activity on CNBC.</li>    <li>Call buying looks notable and observers say $10 calls look cheap.</li>    <li>The stock is down 1.2% in 2017 after spending August coming off a July high of $10.30; now back up to $8.86.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295204\" data-linked=\"Oclaro up 4.4% amid halftime CNBC talk\" data-tweet=\"$OCLR - Oclaro up 4.4% amid halftime CNBC talk https://seekingalpha.com/news/3295204-oclaro-up-4_4-amid-halftime-cnbc-talk?source=tweet\" data-url=\"https://seekingalpha.com/news/3295204-oclaro-up-4_4-amid-halftime-cnbc-talk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295203\" data-ts=\"1505322265\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EMES\" target=\"_blank\">EMES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295203-crude-oil-shoots-higher-on-signs-of-tightening-supply\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil shoots higher on signs of tightening supply</a></h4><ul>     <li>Crude oil futures enjoy solid gains in today's trade, supported by the <a href=\"https://www.ft.com/content/e0571dce-3d5b-3b23-8b1a-8c7f828099b8\" target=\"_blank\">biggest-ever weekly drop</a> in U.S. gasoline inventories and signs that market supply and demand are <a href=\"https://www.wsj.com/articles/oil-rises-on-signs-of-tightening-supply-1505297754\" target=\"_blank\">coming back into balance</a>.</li>     <li>U.S. crude for October delivery currently <font color='green'>+1.6%</font> at $49/bbl in New York, with the global Brent benchmark <font color='green'>+1.2%</font> to $54.92, near a five-month high.</li>     <li>The U.S. Energy Information Administration <a href=\"https://seekingalpha.com/news/3295147-crude-futures-rise-post-inventory-data\" target=\"_blank\">reported</a> that gasoline stockpiles fell by 8.4M barrels in the week ended Sept. 8, while stocks of distillates fell by 3.2M barrels, also exceeding analyst expectations; meanwhile, U.S. refineries ran at at only 78% of operable capacity,  allowing commercial crude oil stocks to rise by 5.9M barrels to  468.2M.</li>     <li>Earlier today, the International Energy Agency said August global oil supplies fell for the first time in four months, while also <a href=\"https://seekingalpha.com/news/3295028-iea-sees-stronger-global-oil-demand\" target=\"_blank\">upwardly revising</a> its 2017 oil demand estimate to 1.6M bbl/day from its July estimate of 1.5M bbl/day.</li>     <li>Energy (<a href='https://seekingalpha.com/symbol/XLE' title='Energy Select Sector SPDR ETF'>XLE</a> <font color='green'>+0.8%</font>) leads all S&amp;P industry groups so far, with some of the day's biggest gainers: <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='green'>+11.9%</font>, <a href='https://seekingalpha.com/symbol/ECR' title='Eclipse Resources'>ECR</a> <font color='green'>+10.5%</font>, <a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='green'>+9.9%</font>, <a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='green'>+9.9%</font>, <a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a> <font color='green'>+9.2%</font>, <a href='https://seekingalpha.com/symbol/WTI' title='W&T Offshore, Inc.'>WTI</a> <font color='green'>+9%</font>, <a href='https://seekingalpha.com/symbol/NE' title='Noble Corporation plc'>NE</a> <font color='green'>+7.9%</font>, <a href='https://seekingalpha.com/symbol/HK' title='Halcon Resources Corporation'>HK</a> <font color='green'>+7.7%</font>, BBG <font color='green'>+7.7%</font>, <a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='green'>+7.3%</font>, <a href='https://seekingalpha.com/symbol/CHK' title='Chesapeake Energy Corporation'>CHK</a> <font color='green'>+7.1%</font>, <a href='https://seekingalpha.com/symbol/ESV' title='Ensco PLC'>ESV</a> <font color='green'>+6.9%</font>, <a href='https://seekingalpha.com/symbol/SN' title='Sanchez Energy Corporation'>SN</a> <font color='green'>+6.9%</font>, <a href='https://seekingalpha.com/symbol/CRR' title='CARBO Ceramics Inc.'>CRR</a> <font color='green'>+6.7%</font>, <a href='https://seekingalpha.com/symbol/TTI' title='Tetra Technologies Inc.'>TTI</a> <font color='green'>+6.7%</font>.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a>, <a href='https://seekingalpha.com/symbol/OILK' title='ProShares K-1 Free Crude Oil Strategy ETF'>OILK</a>, <a href='https://seekingalpha.com/symbol/WTIU' title='ProShares Daily 3x Long Crude ETN'>WTIU</a>, <a href='https://seekingalpha.com/symbol/OILX' title='Etracs S&P GSCI Crude Oil Total Return Index ETN'>OILX</a>, <a href='https://seekingalpha.com/symbol/WTID' title='ProShares Daily 3x Inverse Crude ETN'>WTID</a>, <a href='https://seekingalpha.com/symbol/USOI' title='Credit Suisse Crude Oil Shares Covered Call ETN'>USOI</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3295203\" data-linked=\"Crude oil shoots higher on signs of tightening supply\" data-tweet=\"$EMES $XLE $EMES - Crude oil shoots higher on signs of tightening supply https://seekingalpha.com/news/3295203-crude-oil-shoots-higher-on-signs-of-tightening-supply?source=tweet\" data-url=\"https://seekingalpha.com/news/3295203-crude-oil-shoots-higher-on-signs-of-tightening-supply\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>100&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295202\" data-ts=\"1505322138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GRMN\" target=\"_blank\">GRMN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295202-fitbitplus-3_6-stifel-sees-key-ionic-advantages-over-apple-watch\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit +3.6% as Stifel sees key Ionic advantages over Apple Watch</a></h4><ul>   <li>Fitbit (<a href=\"http://seekingalpha.com/symbol/FIT\" target=\"_blank\">FIT</a> <font color='green'>+3.6%</font>) is seeing a stronger reaction than Garmin (NASDAQ:<a href='https://seekingalpha.com/symbol/GRMN' title='Garmin Ltd.'>GRMN</a>) in the first full day of trading following a key <a href=\"https://seekingalpha.com/news/3294897-apple-iphone-event-2017-live-updates\" target=\"_blank\">wearables announcement from Apple</a>: news of its cellular-capable Apple Watch 3.</li>    <li>Garmin is at $51.93 after closing yesterday at $52.15, but is ex-dividend today after a $0.51 quarterly dividend.</li>    <li>Fitbit's new Ionic <a href=\"www.marketwatch.com/story/fitbits-stock-surges-as-ionic-enjoys-distinctions-compared-with-apple-watch-3-2017-09-13\" target=\"_blank\">enjoys some key differences</a> from Apple's new product, Stifel Nicolaus says.</li>    <li>\"Key distinctions in head-to-head comparison with the Fitbit Ionic product are compatibility with non-iOS devices, longer battery life which supports sleep tracking (claimed 4 days vs. Series 3 watch at 18 hours) and a narrow advantage in price ($299 vs. $329),\" writes analyst Jim Duffy.</li>    <li>And Fitbit is likely to push the message of Ionic's sleep tracking and battery life in the holiday season, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295202\" data-linked=\"Fitbit +3.6% as Stifel sees key Ionic advantages over Apple Watch\" data-tweet=\"$GRMN $GRMN $FIT - Fitbit +3.6% as Stifel sees key Ionic advantages over Apple Watch https://seekingalpha.com/news/3295202-fitbitplus-3_6-stifel-sees-key-ionic-advantages-over-apple-watch?source=tweet\" data-url=\"https://seekingalpha.com/news/3295202-fitbitplus-3_6-stifel-sees-key-ionic-advantages-over-apple-watch\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295200\" data-ts=\"1505321994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295200-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HCI' title='HCI Group, Inc.'>HCI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/HRTG' title='Heritage Insurance Holdings, Inc.'>HRTG</a> <font color='green'>+6%</font>.<a href='https://seekingalpha.com/symbol/FNHC' title='FedNat Holding Company'>FNHC</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/SUPV' title='Grupo Supervielle'>SUPV</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+5%</font>.</li>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AMRK' title='A-Mark Precious Metals, Inc.'>AMRK</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/EFX' title='Equifax Inc.'>EFX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SBNY' title='Signature Bank'>SBNY</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295200\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$HCI $HRTG $FNHC - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3295200-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3295200-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295198\" data-ts=\"1505321534\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/Z\" target=\"_blank\">Z</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295198-zillow-down-after-analyst-suggests-lawsuit-is-forthcoming\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow down after analyst suggests lawsuit is forthcoming</a></h4><ul><li>        Zillow (NASDAQ:<a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a>) shares&nbsp;<font color='red'>down 4.88%</font>&nbsp;after a Susquehanna analyst suggests a lawsuit is coming from the Consumer Financial Protection Bureau &#40;CFPB&#41;.</li><li>Zillow revealed during Q2 earnings last month that CFPB had invited the company to discuss a settlement for an investigation into its co-marketing arrangements. No news has followed the invitation, leading analyst Thomas Claps to believe no deal was reached.&nbsp;</li><li>                  Zillow&rsquo;s co-marking setup currently gives some lenders the ability to subsidize up to 90% of agent costs while other lenders can only subsidize up to 50%.    </li><li>               Claps thinks the CFPB wants Zillow to cap all lenders at 50% and Zillow&rsquo;s failure to agree would lead to a lawsuit, which would reduce revenue and profits.&nbsp;</li><li>               Source: <a href=\"https://thefly.com/landingPageNews.php?id=2608826&amp;headline=Z;ZG-Zillow-slides-as-analyst-says-CFPB-suit-is-likely\" target=\"_blank\">The Fly</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294423-zillow-acquires-listing-management-platform-company\" target=\"_blank\">Zillow acquires listing management platform company</a> (Sept. 8)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295198\" data-linked=\"Zillow down after analyst suggests lawsuit is forthcoming\" data-tweet=\"$Z - Zillow down after analyst suggests lawsuit is forthcoming https://seekingalpha.com/news/3295198-zillow-down-after-analyst-suggests-lawsuit-is-forthcoming?source=tweet\" data-url=\"https://seekingalpha.com/news/3295198-zillow-down-after-analyst-suggests-lawsuit-is-forthcoming\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295197\" data-ts=\"1505321369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295197-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/EGAN' title='eGain Communications Corp.'>EGAN</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/BLDP' title='Ballard Power Systems, Inc.'>BLDP</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/SIEN' title='Sientra'>SIEN</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/AMRS' title='Amyris, Inc.'>AMRS</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/FWP' title='Forward Pharma'>FWP</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RLGT' title='Radiant Logistics, Inc.'>RLGT</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GTXI' title='GTx, Inc.'>GTXI</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295197\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SNAK $EGAN $MYOS - Midday Gainers / Losers https://seekingalpha.com/news/3295197-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3295197-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:49 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295196\" data-ts=\"1505320909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENC\" target=\"_blank\">FENC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295196-fennec-pharmas-lead-product-candidate-shows-treatment-benefit-in-late-stage-study-shares-set\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fennec Pharma&#39;s lead product candidate shows treatment benefit in late-stage study, shares set to rally after end of trading halt</a></h4><ul><li>Ultra-thinly traded micro cap Fennec Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/FENC' title='Fennec Pharmaceuticals, Inc.'>FENC</a>) was up&nbsp;<font color='green'>6%</font>&nbsp;on increased volume, albeit on turnover of only 15K shares, prior to Nasdaq suspending trading pending news. The action will resume at 12:45 pm ET.</li><li>The company just <a href=\"https://seekingalpha.com/pr/16939878-fennec-announces-preliminary-results-siopel-6-study-pedmark-sodium-thiosulfate-presented-49th\" target=\"_blank\">announced </a>preliminary data on lead candidate sodium thiosulfate &#40;STS&#41; that showed a significant effect in reducing chemo-induced hearing loss in children.</li><li>The results showed that the addition of STS to the chemo agent cisplatin reduced the risk of hearing loss by 43% (hazard ratio = 0.57) compared to cisplatin alone. Specifically, the incidence of hearing loss occurred in 38.0% of patients in the Cis + STS arm compared to 65.9% in the Cisplatin-only arm.</li><li>The data will be presented at the International Society of Pediatric Oncology meeting in Washington, D.C. on October 14.</li><li>The company plans to market STS, once approved, under the brand name PEDMARK. It says there are over 7K U.S. and European children with local cancers that may receive platinum-based chemo each year. The survival rates frequently exceed 80% so hearing loss represents a significant morbidity.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>13%.&nbsp;</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3295196\" data-linked=\"Fennec Pharma&#39;s lead product candidate shows treatment benefit in late-stage study, shares set to rally after end of trading halt\" data-tweet=\"$FENC - Fennec Pharma&#39;s lead product candidate shows treatment benefit in late-stage study, shares set to rally after end of trading halt https://seekingalpha.com/news/3295196-fennec-pharmas-lead-product-candidate-shows-treatment-benefit-in-late-stage-study-shares-set?source=tweet\" data-url=\"https://seekingalpha.com/news/3295196-fennec-pharmas-lead-product-candidate-shows-treatment-benefit-in-late-stage-study-shares-set\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295185\" data-ts=\"1505320193\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIEN\" target=\"_blank\">SIEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295185-blair-likes-sientra-upgrades-to-outperform-shares-ahead-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blair likes Sientra, upgrades to Outperform; shares ahead 16%</a></h4><ul><li>Thinly traded micro cap Sientra (<a href='https://seekingalpha.com/symbol/SIEN' title='Sientra'>SIEN</a> <font color='green'>+15.9%</font>) is up on triple normal on the heels of an upgrade to Outperform by William Blair. Analyst Margaret Kaczor says the company's new strategy should start paying off in the year or so. Other positives are the expected FDA approval of a new breast implant manufacturing facility and the upside from its recent takeout of Miramar Labs.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3295185\" data-linked=\"Blair likes Sientra, upgrades to Outperform; shares ahead 16%\" data-tweet=\"$SIEN - Blair likes Sientra, upgrades to Outperform; shares ahead 16% https://seekingalpha.com/news/3295185-blair-likes-sientra-upgrades-to-outperform-shares-ahead-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3295185-blair-likes-sientra-upgrades-to-outperform-shares-ahead-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295184\" data-ts=\"1505320004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LDL\" target=\"_blank\">LDL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295184-lydall-upgraded-to-buy-sidoti-auto-weakness-priced-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lydall upgraded to Buy at Sidoti as auto weakness priced in</a></h4><ul>     <li>Lydall (<a href='https://seekingalpha.com/symbol/LDL' title='Lydall, Inc.'>LDL</a> <font color='green'>+8.3%</font>) shoots higher after Sidoti <a href=\"http://thefly.com/thestreet/realmoney/index.php/LDLid2608682/LDL-Lydall-upgraded-to-Buy-from-Neutral-at-Sidoti\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $62 price target, raised from $54, as the firm expects the company's offerings will outpace automotive peers due to market penetration and concentration in the fibers segment.</li>     <li>Sidoti says risks of 2017 North American automotive weakness are reflected in LDL shares and believes the company offers the best risk/reward in its coverage universe.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295184\" data-linked=\"Lydall upgraded to Buy at Sidoti as auto weakness priced in\" data-tweet=\"$LDL - Lydall upgraded to Buy at Sidoti as auto weakness priced in https://seekingalpha.com/news/3295184-lydall-upgraded-to-buy-sidoti-auto-weakness-priced-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3295184-lydall-upgraded-to-buy-sidoti-auto-weakness-priced-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295177\" data-ts=\"1505318472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295177-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/KNDI' title='Kandi Technologies Group, Inc.'>KNDI</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/LDL' title='Lydall, Inc.'>LDL</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/JVA' title='Coffee Holding Co., Inc'>JVA</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/OBCI' title='Ocean Bio-Chem, Inc.'>OBCI</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IRBT' title='iRobot Corporation'>IRBT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ADOM' title='ADOMANI, Inc.'>ADOM</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FORD' title='Forward Industries, Inc.'>FORD</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/ALCO' title='Alico, Inc.'>ALCO</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295177\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$SNAK $KNDI $LDL - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3295177-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3295177-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295172\" data-ts=\"1505317966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZSAN\" target=\"_blank\">ZSAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295172-zosanos-m207-shows-treatment-effect-in-late-stage-migraine-study-shares-ahead-19\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zosano&#39;s M207 shows treatment effect in late-stage migraine study; shares ahead 19%</a></h4><ul><li>Zosano Pharma (<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma'>ZSAN</a> <font color='green'>+19%</font>) perks up, albeit on light volume, on the heels of a <a href=\"https://seekingalpha.com/pr/16939811-zosano-presents-data-zotrip-study-international-headache-society\" target=\"_blank\">presentation </a>of results from the Phase 2/3 ZOTRIP study assessing lead product candidate M207 for the acute treatment of migraine. The data were presented a the International Headache Society Congress in Vancouver.</li><li>As previously reported, the study met both primary endpoints. 41.5% of patients receiving the 3.8 mg dose of M207 were pain-free at two hours post dose while 31.7% &nbsp;were pain-free 2 - 24 hours post dose and 26.8% pain-free 2 - 48 hours post dose.</li><li>M207 is a zolmitriptan-coated microneedle patch is that is designed to rapidly deliver zolmitriptan during a migraine attack. Zolmitriptan was marketed as a branded medicine by AstraZeneca before coming off patent several years ago. Its development is ongoing.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3242827-zosanos-lead-product-candidate-successful-late-stage-migraine-study-shares-ahead-46-percent\" target=\"_blank\">Zosano's lead product candidate successful in late-stage migraine study; shares ahead 46% premarket</a> (Feb. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295172\" data-linked=\"Zosano&#39;s M207 shows treatment effect in late-stage migraine study; shares ahead 19%\" data-tweet=\"$ZSAN - Zosano&#39;s M207 shows treatment effect in late-stage migraine study; shares ahead 19% https://seekingalpha.com/news/3295172-zosanos-m207-shows-treatment-effect-in-late-stage-migraine-study-shares-ahead-19?source=tweet\" data-url=\"https://seekingalpha.com/news/3295172-zosanos-m207-shows-treatment-effect-in-late-stage-migraine-study-shares-ahead-19\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295171\" data-ts=\"1505317248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/USFD\" target=\"_blank\">USFD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295171-barclays-tees-up-us-foods-outperformer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays tees up US Foods as outperformer</a></h4><ul><li>US Foods (<a href='https://seekingalpha.com/symbol/USFD' title='US Foods Holding'>USFD</a> <font color='green'>+2.6%</font>) rallies after Barclays lifts the food stock to an Overweight rating from Equal-weight.</li><li>The firm points to the lower valuation on US Foods in comparison to peers.</li><li>The new PT on USFD from Barclays goes to $32.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295171\" data-linked=\"Barclays tees up US Foods as outperformer\" data-tweet=\"$USFD - Barclays tees up US Foods as outperformer https://seekingalpha.com/news/3295171-barclays-tees-up-us-foods-outperformer?source=tweet\" data-url=\"https://seekingalpha.com/news/3295171-barclays-tees-up-us-foods-outperformer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295170\" data-ts=\"1505317041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BABA\" target=\"_blank\">BABA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295170-alibaba-announces-super-september-promotion\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alibaba announces Super September promotion</a></h4><ul><li>        Alibaba (NYSE:<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a>) shares&nbsp;<font color='green'>up 1.66%</font>&nbsp;after <a href=\"http://www.prnewswire.com/news-releases/alibabacom-is-helping-lower-cross-border-barriers-with-the-launch-of-super-september-300518890.html\" target=\"_blank\">announcing</a> the Super September promotion that kicks off September 20.</li><li>               Super September focuses on small- and medium-sized buyers and combines lowered prices with low minimum orders and free inspection on orders over $1K to incentivize ordering goods from China.&nbsp;</li><li>               <a href=\"http://www.prnewswire.com/news-releases/alibabacom-is-helping-lower-cross-border-barriers-with-the-launch-of-super-september-300518890.html\" target=\"_blank\">Press release</a>&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294885-alibaba-backing-300m-investment-indian-online-grocer\" target=\"_blank\">Alibaba backing $300M investment in Indian online grocer</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295170\" data-linked=\"Alibaba announces Super September promotion\" data-tweet=\"$BABA - Alibaba announces Super September promotion https://seekingalpha.com/news/3295170-alibaba-announces-super-september-promotion?source=tweet\" data-url=\"https://seekingalpha.com/news/3295170-alibaba-announces-super-september-promotion\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295169\" data-ts=\"1505316949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENBL\" target=\"_blank\">ENBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295169-enable-midstream-to-buy-align-midstream-in-300m-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enable Midstream to buy Align Midstream in $300M deal</a></h4><ul>     <li>Enable Midstream&nbsp;Partners (<a href='https://seekingalpha.com/symbol/ENBL' title='Enable Midstream Partners LP'>ENBL</a> <font color='green'>+1.7%</font>) is higher after <a href=\"https://seekingalpha.com/pr/16938724-enable-midstream-signs-definitive-agreement-acquire-align-midstream\" target=\"_blank\">agreeing to acquire</a> Texas pipeline company Align Midstream from Tailwater Capital for ~$300M.</li>     <li>ENBL says the deal extends its footprint in areas with increasing producer       activity and will be accretive to its 2018 distributable  cash flow per unit.</li>     <li>Align owns natural gas pipeline gathering and processing networks in the Haynesville and Cotton Valley shale plays in east Texas, Louisiana and Arkansas, with 190 miles of gathering pipelines and a processing plant in Panola, Tex.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295169\" data-linked=\"Enable Midstream to buy Align Midstream in $300M deal\" data-tweet=\"$ENBL - Enable Midstream to buy Align Midstream in $300M deal https://seekingalpha.com/news/3295169-enable-midstream-to-buy-align-midstream-in-300m-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3295169-enable-midstream-to-buy-align-midstream-in-300m-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:35 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295167\" data-ts=\"1505316395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLB\" target=\"_blank\">DLB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295167-piper-jaffray-raises-dolby-price-target-estimates-30m-rev-from-iphones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Piper Jaffray raises Dolby price target, estimates $30M rev. from iPhones</a></h4><ul><li>        Piper Jaffray thinks Dolby Labs (NYSE:<a href='https://seekingalpha.com/symbol/DLB' title='Dolby Laboratories, Inc.'>DLB</a>) could get a $20M to $30M revenue boost from iPhone royalties.</li><li>               The company&rsquo;s Vision was included in the new iPhones and the revenue boost estimate is based on prior royalty rates for the devices plus a potential $5M in royalties from the Apple TV.&nbsp;</li><li>                  Dolby likely won&rsquo;t start showing the financial benefits until FY18 due to the late launch of the iPhone X and the Dolby&rsquo;s tendency of recognizing revenue a quarter later. &nbsp;   </li><li>               Piper Jaffray reiterates its Neutral rating but raises the price target from $49 to $52.&nbsp;</li><li>               Source: Bloomberg First Word&nbsp;</li><li>               Dolby shares are&nbsp;<font color='green'>up 9.5%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3295167\" data-linked=\"Piper Jaffray raises Dolby price target, estimates $30M rev. from iPhones\" data-tweet=\"$DLB - Piper Jaffray raises Dolby price target, estimates $30M rev. from iPhones https://seekingalpha.com/news/3295167-piper-jaffray-raises-dolby-price-target-estimates-30m-rev-from-iphones?source=tweet\" data-url=\"https://seekingalpha.com/news/3295167-piper-jaffray-raises-dolby-price-target-estimates-30m-rev-from-iphones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295166\" data-ts=\"1505316233\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHUY\" target=\"_blank\">CHUY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295166-restaurant-stocks-continue-to-recover\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Restaurant stocks continue to recover</a></h4><ul> <li>The restaurant sector is having another strong day on some post-hurricane relief trading. The general tone from restaurant execs has been positive on the pace of recovery in hurricane-impacted regions.</li> <li>Notable gainers today include Chuy's Holdings (<a href='https://seekingalpha.com/symbol/CHUY' title='Chuy&#39;s Holdings'>CHUY</a> <font color='green'>+3%</font>), Red Robin Gourmet Burgers (<a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a> <font color='green'>+3%</font>), Darden Restaurants (<a href='https://seekingalpha.com/symbol/DRI' title='Darden Restaurants, Inc.'>DRI</a> <font color='green'>+3.3%</font>), Dave &amp; Buster's Entertainment (<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='green'>+2.8%</font>), Del Taco (<a href='https://seekingalpha.com/symbol/TACO' title='Del Taco Restaurants, Inc.'>TACO</a> <font color='green'>+3.3%</font>), El Pollo Loco (<a href='https://seekingalpha.com/symbol/LOCO' title='El Pollo Loco Holdings'>LOCO</a> <font color='green'>+2.4%</font>), DineEquity (<a href='https://seekingalpha.com/symbol/DIN' title='Dine Brands Global, Inc.'>DIN</a> <font color='green'>+2.8%</font>), Cheesecake Factory (<a href='https://seekingalpha.com/symbol/CAKE' title='The Cheesecake Factory Incorporated'>CAKE</a> <font color='green'>+2.2%</font>), Ruby Tuesday (<a href='https://seekingalpha.com/symbol/RT' title='Ruby Tuesday, Inc.'>RT</a> <font color='green'>+2.5%</font>), Texas Roadhouse (<a href='https://seekingalpha.com/symbol/TXRH' title='Texas Roadhouse, Inc.'>TXRH</a> <font color='green'>+2.6%</font>), Brinker International (<a href='https://seekingalpha.com/symbol/EAT' title='Brinker International, Inc.'>EAT</a> <font color='green'>+2.9%</font>), Buffalo Wild Wings (<a href='https://seekingalpha.com/symbol/BWLD' title='Buffalo Wild Wings, Inc.'>BWLD</a> <font color='green'>+1.8%</font>) and Chipotle (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='green'>+1.4%</font>).</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/MENU' title='USCF Restaurant Leaders ETF'>MENU</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294923-restaurant-stocks-recover-pre-irma-slide\" target=\"_blank\">Restaurant stocks recover from pre-Irma slide</a> (Sept. 12)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3295166\" data-linked=\"Restaurant stocks continue to recover\" data-tweet=\"$CHUY $CHUY $RRGB - Restaurant stocks continue to recover https://seekingalpha.com/news/3295166-restaurant-stocks-continue-to-recover?source=tweet\" data-url=\"https://seekingalpha.com/news/3295166-restaurant-stocks-continue-to-recover\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295159\" data-ts=\"1505315533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LOXO\" target=\"_blank\">LOXO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295159-loxo-up-15-ahead-of-data-presentation-on-ret-inhibitor-loxominus-292\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loxo up 15% ahead of data presentation on RET inhibitor LOXO-292</a></h4><ul><li>Giddy investors have bid up Loxo Oncology (<a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+15.4%</font>) ahead of next month's <a href=\"https://seekingalpha.com/pr/16939081-loxo-oncology-announces-initial-loxominus-292-clinical-data-presented-late-breaking\" target=\"_blank\">presentation </a>of initial clinical data on LOXO-292 at a lung cancer conference in Japan.&nbsp;The data, to be presented on October 18, will include case reports from two RET fusion-positive lung cancer patients who were previously treated with multikinase inhibitors.</li><li>Phase 1-stage LOXO-292 inhibits RET (rearranged during transfection) kinase. RET fusions occur in ~60% of medullary thyroid cancer cases, as much as 20% of papillary thyroid cancer cases and ~2% of non-small cell lung cancers. RET-expressing tumors, which depend on the kinase for proliferation and survival, are highly sensitive small molecule RET inhibitors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295159\" data-linked=\"Loxo up 15% ahead of data presentation on RET inhibitor LOXO-292\" data-tweet=\"$LOXO - Loxo up 15% ahead of data presentation on RET inhibitor LOXO-292 https://seekingalpha.com/news/3295159-loxo-up-15-ahead-of-data-presentation-on-ret-inhibitor-loxominus-292?source=tweet\" data-url=\"https://seekingalpha.com/news/3295159-loxo-up-15-ahead-of-data-presentation-on-ret-inhibitor-loxominus-292\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295162\" data-ts=\"1505315127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295162-theater-stocks-higher-amid-key-media-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Theater stocks higher amid key media conference</a></h4><ul> <li>AMC Entertainment (<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc'>AMC</a> <font color='green'>+5.3%</font>), IMAX (<a href='https://seekingalpha.com/symbol/IMAX' title='IMAX Corporation'>IMAX</a> <font color='green'>+2.5%</font>) and Cinemark (<a href='https://seekingalpha.com/symbol/CNK' title='Cinemark Holdings, Inc'>CNK</a> <font color='green'>+1.4%</font>) are higher as media execs paint a bright picture on the U.S. box office at the Goldman Sachs Communicopia Conference.</li> <li>The beastly $125M already brought in by <em>It</em> even with Florida and Texas reeling from hurricanes is a major talking point at the conference.</li> <li>Dolby Laboratories (<a href='https://seekingalpha.com/symbol/DLB' title='Dolby Laboratories, Inc.'>DLB</a> <font color='green'>+9.7%</font>) is also rallying on the day. Apart from the theater good cheer, Dolby is seen benefiting from the new lineup of Apple products.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295162\" data-linked=\"Theater stocks higher amid key media conference\" data-tweet=\"$AMC $AMC $IMAX - Theater stocks higher amid key media conference https://seekingalpha.com/news/3295162-theater-stocks-higher-amid-key-media-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3295162-theater-stocks-higher-amid-key-media-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295161\" data-ts=\"1505315034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZAGG\" target=\"_blank\">ZAGG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295161-zagg-sharesplus-7_2-after-announcing-iphone-accessories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zagg shares +7.2% after announcing iPhone accessories</a></h4><ul><li>        Zagg (NASDAQ:<a href='https://seekingalpha.com/symbol/ZAGG' title='ZAGG Inc'>ZAGG</a>) shares&nbsp;<font color='green'>up 7.2%</font>&nbsp;after the company announces accessory products for the new iPhones.</li><li>               The first product is the <a href=\"https://seekingalpha.com/pr/16938748-zagg-announces-mophie-wireless-charging-base-iphone-8-iphone-8-plus-iphone-x\" target=\"_blank\">mophie wireless charging base</a>, a charging pad that works for the iPhone 8, iPhone 8 Plus, and the iPhone X.</li><li>               CEO Randy Hales says the company will update its full year outlook during the upcoming Q3 results and expects the product to have positive contributions in Q4 and FY18.&nbsp;</li><li>               Zagg also announces the <a href=\"https://seekingalpha.com/pr/16939655-invisibleshield-introduces-glass-advanced-tempered-glass-screen-protection-ever-apple-iphone\" target=\"_blank\">Glass+</a> tempered glass screen protector for all three of Apple&rsquo;s new iPhones.&nbsp;</li><li>               The protectors have a suggested retail price of $39.99 and will launch to multiple retailers and carriers on September 22, which is also when the iPhone 8 and 8 Plus become available in stores.&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294897-apple-iphone-event-2017-live-updates\" target=\"_blank\">Apple iPhone Event 2017: Live updates</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295161\" data-linked=\"Zagg shares +7.2% after announcing iPhone accessories\" data-tweet=\"$ZAGG - Zagg shares +7.2% after announcing iPhone accessories https://seekingalpha.com/news/3295161-zagg-sharesplus-7_2-after-announcing-iphone-accessories?source=tweet\" data-url=\"https://seekingalpha.com/news/3295161-zagg-sharesplus-7_2-after-announcing-iphone-accessories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295133\" data-ts=\"1505314850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295133-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/LOXO' title='Loxo Oncology'>LOXO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/BVXV' title='Biondvax Pharmaceuticals'>BVXV</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/RWLK' title='ReWalk Robotics'>RWLK</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/PLSE' title='Pulse Biosciences'>PLSE</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295133\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$MYOS $AKTX $LOXO - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3295133-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3295133-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295153\" data-ts=\"1505313985\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKTX\" target=\"_blank\">AKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295153-akari-therapeutics-continues-up-move-shares-ahead-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akari Therapeutics continues up move; shares ahead 15%</a></h4><ul><li>Thinly traded nano cap Akari Therapeutics (<a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+14.5%</font>) adds to its rally on almost a 9x surge in volume. Shares have doubled since last week on no particular news. A few weeks ago, it appointed a new CEO.</li><li>The company's&nbsp;lead product candidate is&nbsp;<a href=\"http://akaritx.com/coversin/\" target=\"_blank\">Conversin</a>, a second-generation complement inhibitor in development for the treatment of rare disorders paroxysmal nocturnal hemoglobinuria &#40;PNH&#41;, atypical hemolytic uremic syndrome (aHUS) and Guillain Barre syndrome &#40;GBS&#41;.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3290607-akari-therapeutics-appoints-david-horn-solomon-ceo\" target=\"_blank\">Akari Therapeutics appoints David Horn Solomon as CEO</a> (Aug. 21)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295153\" data-linked=\"Akari Therapeutics continues up move; shares ahead 15%\" data-tweet=\"$AKTX - Akari Therapeutics continues up move; shares ahead 15% https://seekingalpha.com/news/3295153-akari-therapeutics-continues-up-move-shares-ahead-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3295153-akari-therapeutics-continues-up-move-shares-ahead-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295151\" data-ts=\"1505313320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MYOS\" target=\"_blank\">MYOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295151-myos-rens-up-23-in-early-trading\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MYOS RENS up 23% in early trading</a></h4><ul><li>Thinly traded nano cap MYOS RENS Technology (<a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+23.2%</font>) is up on a whopping 50x surge in volume, easily breaking through short-term resistance at $1.50. Shares had been in a downtrend since the first of the year. No particular news accounts for the action.</li><li>The company develops and commercializes biotherapeutic and bionutritional products that improve muscle mass. Its lead product is a nutritional supplement called&nbsp;<a href=\"http://www.myosrens.com/bionutrition-products/fortetropin\" target=\"_blank\">Fortetropin</a>, a protein/lipid complex consisting of ~250 proteins, ~50 lipids, a range of peptides and other unnamed molecules isolated from egg yolks.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234758-myos-rens-latest-nano-cap-rocket-shares-jump-four-fold\" target=\"_blank\">MYOS RENS latest nano cap rocket; shares jump over four-fold</a> (Jan. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295151\" data-linked=\"MYOS RENS up 23% in early trading\" data-tweet=\"$MYOS - MYOS RENS up 23% in early trading https://seekingalpha.com/news/3295151-myos-rens-up-23-in-early-trading?source=tweet\" data-url=\"https://seekingalpha.com/news/3295151-myos-rens-up-23-in-early-trading\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295147\" data-ts=\"1505313052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295147-crude-futures-rise-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures rise further post inventory data</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>+5.9M</strong> barrels vs. +3.2M consensus, +4.6M last week.</li>     <li>Gasoline <strong>-8.4M</strong>&nbsp;vs. -2.1M consensus, -3.2M last week.</li>     <li>Distillates <strong>-3.2M</strong> barrels&nbsp;vs. -1.5M consensus, -1.4M last week.</li>     <li>Futures<font color='green'>&nbsp;+1.1%</font>&nbsp;to $48.76.</li>     <li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3295147\" data-linked=\"Crude futures rise further post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures rise further post inventory data https://seekingalpha.com/news/3295147-crude-futures-rise-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3295147-crude-futures-rise-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295142\" data-ts=\"1505312061\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295142-northland-raises-himax-price-target-after-iphone-event\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northland raises Himax price target after iPhone event</a></h4><ul><li>        Northland Capital Markets raises its price target on vertical-cavity surface-emitting laser &#40;VCSEL&#41; company Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>) to $15 and maintains an Outperform rating.</li><li>                  Analyst Tom Sepenzis cites yesterday&rsquo;s Apple launch, which featured the first iPhone with 3D sensing through VCSEL tech, saying he expected &ldquo;more use cases&rdquo; but that &ldquo;much of the premium involves the addition of an OLED infinity display.&rdquo;    </li><li>                  Sepenzis thinks Apple will keep working with developer partners to continue expanding its 3D apps beyond emojis and authentication.    </li><li>               Source: <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Himax+Technologies+%28HIMX%29+PT+Raised+to+%2415+at+Northland+Capital+Markets/13291572.html\" target=\"_blank\">StreetInsider</a>&nbsp;</li><li>               Himax shares are&nbsp;<font color='red'>down 4%</font>.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294171-himax-6_4-percent-oppenheimer-note-response-email\" target=\"_blank\">Himax down 6.4% on Oppenheimer note, response email</a> (Sept. 7)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295142\" data-linked=\"Northland raises Himax price target after iPhone event\" data-tweet=\"$HIMX - Northland raises Himax price target after iPhone event https://seekingalpha.com/news/3295142-northland-raises-himax-price-target-after-iphone-event?source=tweet\" data-url=\"https://seekingalpha.com/news/3295142-northland-raises-himax-price-target-after-iphone-event\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295136\" data-ts=\"1505311463\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMED\" target=\"_blank\">OMED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295136-early-stage-study-of-oncomeds-gitrl-fc-underway-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Early-stage study of OncoMed&#39;s GITRL-Fc underway; shares up 1%</a></h4><ul><li>The first patient has been <a href=\"https://seekingalpha.com/pr/16939315-oncomed-doses-first-patient-gitrl-fc-phase-1a-clinical-trial\" target=\"_blank\">dosed </a>in a Phase 1a study assessing the safety and tolerability of OncoMed Pharmaceuticals' (<a href='https://seekingalpha.com/symbol/OMED' title='OncoMed Pharmaceuticals, Inc'>OMED</a> <font color='green'>+0.9%</font>) GITRL-Fc (OMP-336B11) in patients with advanced or metastatic solid tumors.</li><li>GITRL-Fc is a fusion protein, a costimulatory molecule designed to modulate the tumor microenvironment by inhibiting T-regulatory function and activating T-effector cells.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295136\" data-linked=\"Early-stage study of OncoMed&#39;s GITRL-Fc underway; shares up 1%\" data-tweet=\"$OMED - Early-stage study of OncoMed&#39;s GITRL-Fc underway; shares up 1% https://seekingalpha.com/news/3295136-early-stage-study-of-oncomeds-gitrl-fc-underway-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3295136-early-stage-study-of-oncomeds-gitrl-fc-underway-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295137\" data-ts=\"1505311385\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295137-department-stocks-higher-nordstrom-eyes-private-path\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Department stocks higher as Nordstrom eyes private path</a></h4><ul> <li>Department store stocks are higher after Nordstrom (<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a> <font color='green'>+6%</font>) is reported to be working on a go-private deal.</li> <li>The Nordstrom family is said to be talking to banks about raising debt to finance the deal. Cowen rates the <a href=\"https://www.streetinsider.com/Analyst+Comments/Nordstrom+%28JWN%29%3A+Increasing+Liklihood+Of+LBO+-+Cowen/13290908.html\" target=\"_blank\">odds</a> of go-private deal hitting the finish line at 60% to 70%. \"Confidence and strategies focused on long-term execution plus good long-term visibility into a stabilizing and growing cash flow scenario drives higher likelihood of a deal occurring and securing outside equity,\" writes analyst Oliver Chen.</li> <li>Sector snapshot: J.C. Penney (NYSE:<a href='https://seekingalpha.com/symbol/JCP' title='J.C. Penney Company Inc.'>JCP</a>) <font color='green'>+2.52%</font>, Dillard's (NYSE:<a href='https://seekingalpha.com/symbol/DDS' title='Dillard&#39;s Inc.'>DDS</a>) <font color='green'>+2.24%</font>, Kohl's (NYSE:<a href='https://seekingalpha.com/symbol/KSS' title='Kohl&#39;s Corporation'>KSS</a>) <font color='green'>+1.34%</font>, Macy's (NYSE:<a href='https://seekingalpha.com/symbol/M' title='Macy&#39;s Inc.'>M</a>) <font color='green'>+1.04%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294977-nordstrom-plus-8_2-percent-report-nearing-go-private-deal\" target=\"_blank\">Nordstrom +8.2% on report it's nearing go-private deal</a> (Sept. 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295137\" data-linked=\"Department stocks higher as Nordstrom eyes private path\" data-tweet=\"$JWN $JWN $JCP - Department stocks higher as Nordstrom eyes private path https://seekingalpha.com/news/3295137-department-stocks-higher-nordstrom-eyes-private-path?source=tweet\" data-url=\"https://seekingalpha.com/news/3295137-department-stocks-higher-nordstrom-eyes-private-path\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295130\" data-ts=\"1505310765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/POWI\" target=\"_blank\">POWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295130-power-integrations-down-after-rosenblatt-sees-limited-growth-potential\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Integrations down after Rosenblatt sees limited growth potential</a></h4><ul><li>        Rosenblatt says Power Integrations (NASDAQ:<a href='https://seekingalpha.com/symbol/POWI' title='Power Integrations, Inc.'>POWI</a>) has likely lost Apple as a customer for its fast-charging Inno-Switch, per <a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">Notable Calls</a>.</li><li>               Rosenblatt says that without Apple or production adoption in China, Power Integrated has limited market growth potential in 2018. &nbsp;&nbsp;&nbsp;</li><li>Power Integrations shares are&nbsp;<font color='red'>down 5.45%</font>. &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3295130\" data-linked=\"Power Integrations down after Rosenblatt sees limited growth potential\" data-tweet=\"$POWI - Power Integrations down after Rosenblatt sees limited growth potential https://seekingalpha.com/news/3295130-power-integrations-down-after-rosenblatt-sees-limited-growth-potential?source=tweet\" data-url=\"https://seekingalpha.com/news/3295130-power-integrations-down-after-rosenblatt-sees-limited-growth-potential\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295128\" data-ts=\"1505310594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FENC\" target=\"_blank\">FENC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295128-fennec-pharma-uplisted-to-nasdaq-capital-market-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fennec Pharma uplisted to Nasdaq Capital Market today</a></h4><ul><li>Fennec Pharmaceuticals (FENCF) will begin trading on Nasdaq Capital Market today under the symbol \"FENC.\"</li><li>Its lead product candidate is <a href=\"http://fennecpharma.com/product-candidates/sts/\" target=\"_blank\">sodium thiosulfate</a> &#40;STS&#41; for the prevention of chemo-induced hearing loss in children.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295128\" data-linked=\"Fennec Pharma uplisted to Nasdaq Capital Market today\" data-tweet=\"$FENC - Fennec Pharma uplisted to Nasdaq Capital Market today https://seekingalpha.com/news/3295128-fennec-pharma-uplisted-to-nasdaq-capital-market-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3295128-fennec-pharma-uplisted-to-nasdaq-capital-market-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295116\" data-ts=\"1505308792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RETA\" target=\"_blank\">RETA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295116-reatas-omaveloxolone-orphan-drug-for-melanoma-shares-up-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reata&#39;s omaveloxolone an Orphan Drug for melanoma; shares up 2% premarket</a></h4><ul><li>Thinly traded small cap Reata Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/RETA' title='Reata Pharmaceuticals'>RETA</a>) is up&nbsp;<font color='green'>2%</font>&nbsp;premarket, albeit on only 111 shares, on the heels of the FDA's Orphan Drug <a href=\"https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=461114\" target=\"_blank\">designation</a> for omaveloxolone for stage IIb - IV malignant melanoma. A <a href=\"https://clinicaltrials.gov/ct2/show/NCT02259231?term=omaveloxolone&amp;rank=4\" target=\"_blank\">Phase 1/2 study</a>&nbsp;is in process with an estimated completion date of March 2019.</li><li>Omaveloxolone is an&nbsp;<a href=\"https://reatapharma.com/our-science/nrf2-activators/\" target=\"_blank\">antioxidant inflammation modulator</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295116\" data-linked=\"Reata&#39;s omaveloxolone an Orphan Drug for melanoma; shares up 2% premarket\" data-tweet=\"$RETA - Reata&#39;s omaveloxolone an Orphan Drug for melanoma; shares up 2% premarket https://seekingalpha.com/news/3295116-reatas-omaveloxolone-orphan-drug-for-melanoma-shares-up-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3295116-reatas-omaveloxolone-orphan-drug-for-melanoma-shares-up-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295113\" data-ts=\"1505308742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQM\" target=\"_blank\">SQM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295113-sqmplus-2_5-on-bofa-merrill-upgrade-best-positioned-lithium-player\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SQM +2.5% on BofA Merrill upgrade as best positioned lithium player</a></h4><ul>     <li>Sociedad Quimica y Minera de Chile (NYSE:<a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a>) <font color='green'>+2.5%</font> premarket after BofA&nbsp;Merrill Lynch <a href=\"https://www.streetinsider.com/Analyst+Comments/BofAMerrill+Lynch+Upgrades+Sociedad+Quimica+y+Minera+%28SQM%29+to+Buy%2C+Positively+Revises+FY+20171819+EPS+Estimates/13291128.html\" target=\"_blank\">upgrades shares to Buy</a> from Neutral with a $65 price target, hiked from $49, as the \"best positioned lithium story\" should extend the rally that has lifted shares nearly 8% <a href=\"https://seekingalpha.com/news/3294673-lithium-producers-party-china-mulls-ban-fossil-fuel-vehicles\" target=\"_blank\">this week</a> and 27% higher over the past month.</li><li>BAML notes the U.K., France, Germany and China have all announced plans to <a href=\"https://twitter.com/thenotablecalls/status/907951305313964032\" target=\"_blank\">eventually ban sales of gasoline and diesel cars</a> and replace them with electric vehicles, and calculates that roughly <a href=\"https://twitter.com/thenotablecalls/status/907951337035501570\" target=\"_blank\">half of marginal demand for cars</a> in the world will be for EVs in 15-20 years.</li><li>BAML goes on to forecast implied global demand for lithium of 640K tons by 2025, <a href=\"https://twitter.com/thenotablecalls/status/907951356115406848\" target=\"_blank\">more than triple current demand</a>, and the firm says SQM is the best positioned player in the lithium industry.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295113\" data-linked=\"SQM +2.5% on BofA Merrill upgrade as best positioned lithium player\" data-tweet=\"$SQM - SQM +2.5% on BofA Merrill upgrade as best positioned lithium player https://seekingalpha.com/news/3295113-sqmplus-2_5-on-bofa-merrill-upgrade-best-positioned-lithium-player?source=tweet\" data-url=\"https://seekingalpha.com/news/3295113-sqmplus-2_5-on-bofa-merrill-upgrade-best-positioned-lithium-player\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295109\" data-ts=\"1505308268\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295109-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li>ITEK&nbsp;<font color='red'>-8%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3294978-inotek-pharma-merge-gene-therapy-developer-rocket-pharmaceuticals\" target=\"_blank\">announcing</a> merger agreement with Rocket Pharmaceuticals.</li><li><a href='https://seekingalpha.com/symbol/WATT' title='Energous Corp.'>WATT</a>&nbsp;<font color='red'>-8%</font>&nbsp;after Apple <a href=\"https://seekingalpha.com/news/3294949-energous-plunges-apple-announces-different-path-wireless-charging\" target=\"_blank\">announcing</a> different path to wireless charging.</li><li><a href='https://seekingalpha.com/symbol/TCMD' title='Tactile Systems Technology'>TCMD</a> <font color='red'>-6%</font>&nbsp;on pricing secondary offering of common stock.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3295109\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$RCKT $WATT $TCMD - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3295109-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3295109-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295105\" data-ts=\"1505307742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXRX\" target=\"_blank\">LXRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295105-lexicon-pharma-announces-publication-of-results-from-third-late-stage-study-of-diabetes-med\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lexicon Pharma announces publication of results from third late-stage study of diabetes med sotagliflozin; shares ease 2% premarket</a></h4><ul><li>Lexicon Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/LXRX' title='Lexicon Pharmaceuticals, Inc.'>LXRX</a>) <a href=\"https://seekingalpha.com/pr/16939011-new-england-journal-medicine-publishes-data-phase-3-intandem3-study-sotagliflozin-patients\" target=\"_blank\">announces </a>the publication of results from the Phase 3 Tandem3 study assessing dual SGLT1 and SGLT2 inhibitor sotagliflozin in type 1 diabetics in the <em>New England Journal of Medicine</em>. The online publication coincides with the presentation of data at the European Association for the Study of Diabetes conference in Lisbon, Portugal.</li><li>The study met its primary endpoint of demonstrating sotagliflozin's (400 mg) superiority to placebo as measured by the proportion of patients achieving &lt;7.0% HbA1c at week 24 and no episode of severe hypoglycemia and no episode of diabetic ketoacidosis &#40;DKA&#41; after randomization.</li><li>Patients in the treatment group experienced a mean body weight reduction from baseline of 2.2 kg compared to a mean gain of 0.8 kg in the control group. Patients receiving sotagliflozin also experienced a larger drop in systolic blood pressure and the amount of bolus insulin used.</li><li>Sotagliflozin's safety profile was consistent with those observed in Tandem1 and Tandem2. The rate of severe hypoglycemia was 3.0% over the treatment period compared to 2.4% for placebo. The rate of DKA was also higher, 3.0% vs. 0.6%.</li><li>Shares are down&nbsp;<font color='red'>2%&nbsp;</font>premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272571-lexicon-pharmas-sotagliflozin-successful-third-late-stage-diabetes-study\" target=\"_blank\">Lexicon Pharma's sotagliflozin successful in third late-stage diabetes study</a> (June 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295105\" data-linked=\"Lexicon Pharma announces publication of results from third late-stage study of diabetes med sotagliflozin; shares ease 2% premarket\" data-tweet=\"$LXRX - Lexicon Pharma announces publication of results from third late-stage study of diabetes med sotagliflozin; shares ease 2% premarket https://seekingalpha.com/news/3295105-lexicon-pharma-announces-publication-of-results-from-third-late-stage-study-of-diabetes-med?source=tweet\" data-url=\"https://seekingalpha.com/news/3295105-lexicon-pharma-announces-publication-of-results-from-third-late-stage-study-of-diabetes-med\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295101\" data-ts=\"1505307532\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGO\" target=\"_blank\">EGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295101-greece-says-will-grant-permits-for-eldorado-golds-olympias-project-this-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Greece says will grant permits for Eldorado Gold&#39;s Olympias project this week</a></h4><ul>     <li>Eldorado Gold (NYSE:<a href='https://seekingalpha.com/symbol/EGO' title='Eldorado Gold Corporation'>EGO</a>)&nbsp;<font color='green'>+4%</font> premarket after Greece's Energy Minister tells protesting mine workers that the government <a href=\"http://www.reuters.com/article/us-eldorado-gold-greece/greece-to-grant-permits-for-eldorado-golds-olympias-project-this-week-minister-idUSKCN1BO17M\" target=\"_blank\">will grant outstanding permits this week</a> to enable the company to fully operate the Olympias mine.</li>     <li>EGO threatened earlier this week to suspend investment at Olympias and two other Greek projects, demanding permits and clarifications on an upcoming arbitration process, and dozens of mine workers rallied outside the energy ministry in protest at potential job losses.</li>     <li>Disputes over the mining investments have dragged on for years, especially over compliance with environmental regulations.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295101\" data-linked=\"Greece says will grant permits for Eldorado Gold&#39;s Olympias project this week\" data-tweet=\"$EGO - Greece says will grant permits for Eldorado Gold&#39;s Olympias project this week https://seekingalpha.com/news/3295101-greece-says-will-grant-permits-for-eldorado-golds-olympias-project-this-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3295101-greece-says-will-grant-permits-for-eldorado-golds-olympias-project-this-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295100\" data-ts=\"1505307266\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295100-goldman-sachs-upgrades-micron-technology\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs upgrades Micron Technology</a></h4><ul><li>        Goldman Sachs upgrades Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) from Neutral to Buy with a $40 price target.</li><li>               Analyst Mark Delaney sees Micron benefitting from potential Q4 industry trends including increased DRAM pricing and flat to increased NAND pricing. The DRAM cycle could stay tight through next year.&nbsp;</li><li>               Delaney says the conditions imply a 20% upside to Q1 estimates in 2018 and 25% upside to FY18.&nbsp;</li><li>               The analyst also sees value in Micron as it trades near the bottom of the historical P/E range and at an up to 40% discount on its peers.&nbsp;</li><li>               Source: <a href=\"https://www.streetinsider.com/Analyst+Comments/Goldman+Sachs+Upgrades+Micron+Technology+%28MU%29+to+Buy/13289952.html\" target=\"_blank\">StreetInsider</a>&nbsp;</li><li>Micron Technology shares are&nbsp;<font color='green'>up 1.2%</font>&nbsp;premarket. &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3294894-jpmorgan-says-broadcom-micron-benefit-apple-launch\" target=\"_blank\">JPMorgan says Broadcom, Micron could benefit from Apple launch</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295100\" data-linked=\"Goldman Sachs upgrades Micron Technology\" data-tweet=\"$MU - Goldman Sachs upgrades Micron Technology https://seekingalpha.com/news/3295100-goldman-sachs-upgrades-micron-technology?source=tweet\" data-url=\"https://seekingalpha.com/news/3295100-goldman-sachs-upgrades-micron-technology\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>46&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295099\" data-ts=\"1505306732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBRL\" target=\"_blank\">CBRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295099-on-cracker-barrels-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Cracker Barrel&#39;s Q4</a></h4><ul>     <li>Cracker Barrel (NASDAQ:<a href='https://seekingalpha.com/symbol/CBRL' title='Cracker Barrel Old Country Store, Inc.'>CBRL</a>)&nbsp;reports comparable restaurant sales fell 0.8% in <a href=\"https://seekingalpha.com/pr/16939286-cracker-barrel-reports-fourth-quarter-full-year-fiscal-2017-results-provides-guidance-fiscal\" target=\"_blank\">Q4</a>, including a 1.7% decrease in store traffic partially offset by a 0.9% increase in average check.</li>     <li>Comparable retail sales declined 4.4% for the quarter.</li>     <li>The average menu price increased ~1.4%.</li>     <li>Restaurant revenue rose 0.3% to $611.32M and retail revenue dropped 3.1% to $131.9M.</li>     <li>Operating margin rate improved 80 bps to 11.2%.</li>     <li>The company expects Q1 diluted EPS in the range of $1.85 to $1.95.</li>     <li>Store count +8 Y/Y to 649.</li>     <li><b>FY2018 Guidance</b>: Total revenue: ~$3.1B; Comparable store restaurant sales: +2.5% to +3.5%; Comparable store retail sales: +0.0% to 1%; Depreciation expense: $95M to $100M; Net interest expense: $16M to $17M; Diluted&nbsp;EPS of $8.85 to $9; Operating margin rate: 10% to 10.5%; Capex: ~$150M to $160M; Tax rate: 31% to 32%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295099\" data-linked=\"More on Cracker Barrel&#39;s Q4\" data-tweet=\"$CBRL - More on Cracker Barrel&#39;s Q4 https://seekingalpha.com/news/3295099-on-cracker-barrels-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3295099-on-cracker-barrels-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295094\" data-ts=\"1505305947\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSTI\" target=\"_blank\">PSTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295094-pluristem-awarded-two-patents-in-hong-kong-covering-cell-therapy-for-cli-and-muscle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pluristem awarded two patents in Hong Kong covering cell therapy for CLI and muscle regeneration; shares up 3% premarket</a></h4><ul><li>Thinly traded micro cap Pluristem Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PSTI' title='Pluristem Therapeutics, Inc.'>PSTI</a>) is up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16939100-pluristem-strengthens-position-asia-awarded-two-new-patents-hong-kong-critical-limb-ischemia\" target=\"_blank\">announcement </a>that the Hong Kong Patents Registry has issued it two patents protecting its cell therapy products for use in treating critical limb ischemia &#40;CLI&#41; and muscle regeneration.</li><li>Specifically, the first patent covers the use of mesenchymal stem cells to treat skeletal muscle damage or injury and the second for the use of adherent cells to treat ischemia and for connective tissue regeneration and repair.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295094\" data-linked=\"Pluristem awarded two patents in Hong Kong covering cell therapy for CLI and muscle regeneration; shares up 3% premarket\" data-tweet=\"$PSTI - Pluristem awarded two patents in Hong Kong covering cell therapy for CLI and muscle regeneration; shares up 3% premarket https://seekingalpha.com/news/3295094-pluristem-awarded-two-patents-in-hong-kong-covering-cell-therapy-for-cli-and-muscle?source=tweet\" data-url=\"https://seekingalpha.com/news/3295094-pluristem-awarded-two-patents-in-hong-kong-covering-cell-therapy-for-cli-and-muscle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295083\" data-ts=\"1505304907\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OTIC\" target=\"_blank\">OTIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295083-otonomy-restructures-after-otividex-flop-1-3-of-non-commercial-workforce-cut-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Otonomy restructures after Otividex flop; 1/3 of non-commercial workforce cut; shares up 1% premarket</a></h4><ul><li>Otonomy (NASDAQ:<a href='https://seekingalpha.com/symbol/OTIC' title='Otonomy'>OTIC</a>) <a href=\"https://seekingalpha.com/pr/16939170-otonomy-provides-business-financial-update\" target=\"_blank\">announces </a>a restructuring initiative aimed at cutting operating expenses and extending its cash runway after the failed Phase 3 study of OTIVIDEX in M&eacute;ni&egrave;re&rsquo;s disease. Key points (some announced previously):</li><li>All OTIVIDEX development activities have been suspended.</li><li>One third of the personnel not involved in OTIPRO (ciprofloxacin otic suspension) commercial support will be terminated.</li><li>No clinical trials will be initiated for the remainder of 2017. The timing for the start of the Phase 2 study of OTO-311 (gacyclidine) in tinnitus and the Phase 3 of OTIPRO in pediatric patients with acute otitis media with tympanostomy tubes will be evaluated and prioritized as part of the pipeline review.</li><li>Cash consumption should be no more than $45M in 2018. The balance of quick assets (cash, cash equivalents and short-term investments) should be $120M - 125M at the end of this year.&nbsp;Cost savings should be ~$7M for the remainder of 2017.</li><li>The commercial organization will continue its efforts increase OTIPRO utilization during ear tube surgery.</li><li>The FDA's action date for the sNDA for acute otitis externa is March 2, 2018.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3292591-otonomys-otividex-flunks-late-stage-study-meniere-s-diease\" target=\"_blank\">Otonomy's Otividex flunks late-stage study in M&eacute;ni&egrave;re&rsquo;s disease</a> (Aug. 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295083\" data-linked=\"Otonomy restructures after Otividex flop; 1/3 of non-commercial workforce cut; shares up 1% premarket\" data-tweet=\"$OTIC - Otonomy restructures after Otividex flop; 1/3 of non-commercial workforce cut; shares up 1% premarket https://seekingalpha.com/news/3295083-otonomy-restructures-after-otividex-flop-1-3-of-non-commercial-workforce-cut-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3295083-otonomy-restructures-after-otividex-flop-1-3-of-non-commercial-workforce-cut-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295090\" data-ts=\"1505304841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEX\" target=\"_blank\">TEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295090-mick-mcguire-says-terex-is-best-idea\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mick McGuire says Terex is his best idea</a></h4><ul>     <li>Terex (NYSE:<a href='https://seekingalpha.com/symbol/TEX' title='Terex Corporation'>TEX</a>) <font color='green'>+3.4%</font>&nbsp;premarket and building on yesterday's 4.2% rally after Marcato Capital&rsquo;s Mick McGuire says the stock is the activist hedge fund's <a href=\"https://www.cnbc.com/2017/09/12/marcato-capital-sets-eyes-on-construction-equipment-maker.html\" target=\"_blank\">biggest holding</a>.</li><li>McGuire says TEX's revenue should increase if expectations for economic growth come to fruition; he says he began snapping up shares last year and now owns 6% of the company.</li><li>Mercato just finished a bitter proxy battle at Buffalo Wild Wings, where it won three board seats and led to the resignation of CEO&nbsp;Sally Smith.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295090\" data-linked=\"Mick McGuire says Terex is his best idea\" data-tweet=\"$TEX - Mick McGuire says Terex is his best idea https://seekingalpha.com/news/3295090-mick-mcguire-says-terex-is-best-idea?source=tweet\" data-url=\"https://seekingalpha.com/news/3295090-mick-mcguire-says-terex-is-best-idea\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295077\" data-ts=\"1505303457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDRL\" target=\"_blank\">SDRL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295077-no-recovery-for-north-atlantic-drilling-shareholders-in-chapter-11\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">No recovery for North Atlantic Drilling shareholders in Chapter 11</a></h4><ul>     <li>Seadrill (NYSE:<a href='https://seekingalpha.com/symbol/SDRL' title='Seadrill Limited &#40;New&#41;'>SDRL</a>) subsidiary North Atlantic Drilling (NYSE:<a href='https://seekingalpha.com/symbol/NADL' title='North Atlantic Drilling Ltd.'>NADL</a>) says <a href=\"http://www.nadlcorp.com/investors/news/news-release?ResultPageURL=http://cws.huginonline.com/N/155697/PR/201709/2133720.xml\" target=\"_blank\">shareholders will receive no recovery</a> in SDRL's <a href=\"https://seekingalpha.com/news/3295011-seadrill-files-bankruptcy-updated\" target=\"_blank\">Chapter 11 process</a>.</li>     <li>SDRL earlier announced it had filed for Chapter 11 and expects current SDRL shareholders to receive 2% of the post-restructured equity.</li><li>NADL&nbsp;<font color='red'>-10.7%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295077\" data-linked=\"No recovery for North Atlantic Drilling shareholders in Chapter 11\" data-tweet=\"$SDRL $SDRL $NADL - No recovery for North Atlantic Drilling shareholders in Chapter 11 https://seekingalpha.com/news/3295077-no-recovery-for-north-atlantic-drilling-shareholders-in-chapter-11?source=tweet\" data-url=\"https://seekingalpha.com/news/3295077-no-recovery-for-north-atlantic-drilling-shareholders-in-chapter-11\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295073\" data-ts=\"1505302722\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295073-susquehanna-expects-finish-line-buyout\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Susquehanna expects Finish Line buyout</a></h4><ul> <li>Susuquehanna lifts Finish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) to a Positive rating on a M&amp;A call after having the retailer set at Neutral.</li> <li>The firm raises the odds of a Finish Line acquisition by Sports Direct to 75% at a price of around $13.30.</li> <li>The price target on FINL is hiked up to $12 from $9.</li><li>Source: Bloomberg</li> <li>FINL <font color='green'>+2.36%</font> premarket to $9.97.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3295073\" data-linked=\"Susquehanna expects Finish Line buyout\" data-tweet=\"$FINL - Susquehanna expects Finish Line buyout https://seekingalpha.com/news/3295073-susquehanna-expects-finish-line-buyout?source=tweet\" data-url=\"https://seekingalpha.com/news/3295073-susquehanna-expects-finish-line-buyout\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295071\" data-ts=\"1505302562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295071-western-digital-issues-statement-on-toshibas-chip-unit-bid-selection\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Western Digital issues statement on Toshiba&#39;s chip unit bid selection</a></h4><ul><li>Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) issues a statement to Seeking Alpha responding to this morning&rsquo;s report that a different consortium has signed a letter of intent to buy Toshiba&rsquo;s (<a href='https://seekingalpha.com/symbol/TOSBF' title='Toshiba Corp.'>OTCPK:TOSBF</a>, <a href='https://seekingalpha.com/symbol/TOSYY' title='Toshiba Corp. ADR'>OTCPK:TOSYY</a>) chip unit.</li><li>Statement:&nbsp;&ldquo;We are disappointed that Toshiba would take this action despite Western Digital&rsquo;s tireless efforts to reach a resolution that is in the best interests of all stakeholders. Throughout our ongoing dialogue with Toshiba, we have been flexible, constructive and have submitted numerous proposals to specifically address Toshiba&rsquo;s stated concerns. Our goal has been&nbsp;&mdash;&nbsp;and remains&nbsp;&mdash;&nbsp;to reach a mutually beneficial outcome that satisfies the needs of Toshiba and its stakeholders, and most importantly, ensures the longevity and continued success of the JVs.\"</li><li>\"Furthermore, it is surprising that Toshiba would continue to pursue a transaction with a consortium led by&nbsp;Korea-based SK Hynix Inc. and Bain Capital Japan&nbsp;without SanDisk&rsquo;s consent, as the language in the relevant JV agreements is unambiguous, and multiple courts have ruled in favor of protecting SanDisk&rsquo;s contractual rights. We remain confident in our ability to protect our JV interests and consent rights.&rdquo;</li><li>Western Digital shares are&nbsp;<font color='red'>down 3.68%</font>&nbsp;premarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3295021-bain-apple-closer-buying-toshiba-unit\" target=\"_blank\">Bain-Apple closer to buying Toshiba unit</a> (Sept. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295071\" data-linked=\"Western Digital issues statement on Toshiba&#39;s chip unit bid selection\" data-tweet=\"$WDC $WDC $TOSBF - Western Digital issues statement on Toshiba&#39;s chip unit bid selection https://seekingalpha.com/news/3295071-western-digital-issues-statement-on-toshibas-chip-unit-bid-selection?source=tweet\" data-url=\"https://seekingalpha.com/news/3295071-western-digital-issues-statement-on-toshibas-chip-unit-bid-selection\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295055\" data-ts=\"1505301034\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGNC\" target=\"_blank\">AGNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295055-agnc-investment-down-3_5-after-pricing-secondary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AGNC Investment down 3.5% after pricing secondary</a></h4><ul><li>The company sold 24.5M shares for gross proceeds of $510.8M, suggesting a sale price of about $20.85 each.</li><li><a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a>&nbsp;<font color='red'>-3.5%</font>&nbsp;premarket to $20.75</li><li>Source:&nbsp;<a href=\"https://seekingalpha.com/pr/16938928-b-agnc-b-investment-corp-announces-pricing-public-offering-common-stock\" target=\"_blank\">Press Release</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3294966-agnc-investment-another-capital-raise-shares-2_5-percent-hours\" target=\"_blank\">AGNC Investment with another capital raise; shares down 2.5% after hours</a> (Sept. 12)</li></ul><div class=\"tiny-share-widget\" data-id=\"3295055\" data-linked=\"AGNC Investment down 3.5% after pricing secondary\" data-tweet=\"$AGNC - AGNC Investment down 3.5% after pricing secondary https://seekingalpha.com/news/3295055-agnc-investment-down-3_5-after-pricing-secondary?source=tweet\" data-url=\"https://seekingalpha.com/news/3295055-agnc-investment-down-3_5-after-pricing-secondary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295053\" data-ts=\"1505300980\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295053-amicus-therapeutics-sdminus-101-flunks-late-stage-study-in-epidermolysis-bullosa-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amicus Therapeutics&#39; SD-101 flunks late-stage study in epidermolysis bullosa; shares down 13% premarket</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) slumps&nbsp;<font color='red'>13%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16939045-amicus-therapeutics-announces-top-line-phase-3-results-sdminus-101-epidermolysis-bullosa\" target=\"_blank\">announcement </a>that a Phase 3 clinical trial assessing wound-healing agent SD-101 in patients with epidermolysis bullosa failed to achieve its primary and secondary endpoints.</li><li>The 169-subject study, ESSENCE, failed to demonstrate a treatment effect from SD-101 versus placebo. The co-primary endpoints were time-to-target wound closure within three months (no difference between the treatment and placebo arms) and the proportion of patients achieving target wound closure at month 3 (49% for SD-101 vs. 54% for placebo).</li><li>The company plans to continue its analysis. It will cease development for the indication.</li><li>Management will host a conference call this morning at 8:30 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295053\" data-linked=\"Amicus Therapeutics&#39; SD-101 flunks late-stage study in epidermolysis bullosa; shares down 13% premarket\" data-tweet=\"$FOLD - Amicus Therapeutics&#39; SD-101 flunks late-stage study in epidermolysis bullosa; shares down 13% premarket https://seekingalpha.com/news/3295053-amicus-therapeutics-sdminus-101-flunks-late-stage-study-in-epidermolysis-bullosa-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3295053-amicus-therapeutics-sdminus-101-flunks-late-stage-study-in-epidermolysis-bullosa-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295043\" data-ts=\"1505300227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTLA\" target=\"_blank\">PTLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295043-portola-pharmaceuticals-prices-stock-offering-55_00-cancels-morgan-stanley-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Portola Pharmaceuticals prices stock offering at $55.00, cancels Morgan Stanley presentation</a></h4><ul><li>Portola Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PTLA' title='Portola Pharmaceuticals'>PTLA</a>) <a href=\"https://seekingalpha.com/pr/16938939-portola-announces-pricing-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 6.35M shares of common stock at $55.00 per share. Underwriters over-allotment is an additional 952.5K shares. Closing date is September 15.</li><li>The company has canceled its presentation today at the Morgan Stanley Global Healthcare Conference.</li><li>Yesterday's close was $56.96.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295043\" data-linked=\"Portola Pharmaceuticals prices stock offering at $55.00, cancels Morgan Stanley presentation\" data-tweet=\"$PTLA - Portola Pharmaceuticals prices stock offering at $55.00, cancels Morgan Stanley presentation https://seekingalpha.com/news/3295043-portola-pharmaceuticals-prices-stock-offering-55_00-cancels-morgan-stanley-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3295043-portola-pharmaceuticals-prices-stock-offering-55_00-cancels-morgan-stanley-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3295039\" data-ts=\"1505299945\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3295039-biocryst-prices-stock-offering-5_15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst prices stock offering at $5.15</a></h4><ul><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) <a href=\"https://seekingalpha.com/pr/16938927-biocryst-pharmaceuticals-prices-public-offering-common-stock\" target=\"_blank\">prices </a>its public offering of 15,533,981 shares of common stock at $5.15 per share. Underwriters over-allotment is an additional 2,330,097 shares. Closing date is September 15.</li><li>Net proceeds will be used for general corporate purposes.</li><li>Yesterday's close was $5.23.</li></ul><div class=\"tiny-share-widget\" data-id=\"3295039\" data-linked=\"BioCryst prices stock offering at $5.15\" data-tweet=\"$BCRX - BioCryst prices stock offering at $5.15 https://seekingalpha.com/news/3295039-biocryst-prices-stock-offering-5_15?source=tweet\" data-url=\"https://seekingalpha.com/news/3295039-biocryst-prices-stock-offering-5_15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":72,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}